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ABSTRACT 
 
PART I: AN INVESTIGATION OF CALCITROIC ACID AND ITS PHASE II CONJUGATES 
by 
Olivia B. Yu 
The University of Wisconsin-Milwaukee, 2019 
Under the Supervision of Professor Alexander Arnold 
 
 
Calcitroic acid (CTA) was isolated and characterized more than four decades ago.5 
Radiolabeled calcitriol (1,25-dihydroxyvitamin D3) was used at that time to enable the 
identification of radioactive CTA formed in vivo, which was subsequently extracted and 
characterized by derivatization.7 CTA was found to be predominantly formed in the liver and 
secreted into the gut through the bile duct via enterohepatic circulation, leading to fairly high 
concentrations of this metabolite of vitamin D in the intestine.8 However, assuming it was only a 
catabolic product of calcitriol, it was ignored thereafter. 
Recently, novel experiments showed that CTA can bind the vitamin D receptor (VDR) and 
initiate gene regulation of certain metabolic enzymes.4 The VDR is a nuclear hormone receptor 
and is present in many tissues.9 VDR is a biological sensor with the ability to bind several 
endogenous ligands. Calcitriol has the highest known affinity for VDR and has been very 
thoroughly investigated. In contrast to that, very little is known about the main final metabolite 
of vitamin D: calcitroic acid. Because its binding to VDR is weaker than calcitriol, it was presumed 
to be biologically inactive at the time of its discovery. 
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Gene regulation in the presence of CTA has now been demonstrated in epithelia, 
keratinocytes, and prostate cancer cells.8 One assumed function of VDR in the intestine is the 
regulation of P450 enzymes. These are important enzymes for detoxification, especially with 
respect to harmful accumulation of toxic endogenous small molecules, such as lithocholic acid. 
Our hypothesis is that CTA regulates this process in conjunction with VDR for the purpose of 
preventing the development of inflammation-based gastrointestinal diseases such as irritable 
bowel syndrome, or even colorectal cancer. 
My research has been focused on producing CTA synthetically and testing its effects in 
vitro and in vivo. Due to it being unavailable for purchase at a reasonable price and the difficulty 
of its synthesis, much of my research was focused on modifying and optimizing a lengthy 
synthetic route to the final product. Secondarily, I generated 13C-labeled CTA to be used as an 
isotopic standard to enable the quantification of CTA in bodily fluids. Several proposed phase 
two conjugates of CTA and the recently discovered other final vitamin D metabolite calcioic acid 
were also synthesized following novel synthetic routes. We confirmed the binding between 
these analogs and VDR. The availability of CTA conjugates will support their quantification in vivo 
in future studies using LCMS/MS and MALDI-TOF/TOF. Additionally, VDR’s expression in 
leukocytes has shown immune suppression influence with calcitriol as its ligand. Studies with CTA 
and its conjugates also have indicated similar anti-inflammatory effects. Further studies will be 
conducted to determine whether CTA or its conjugates have any of the suspected detoxification 
properties in the gut.   
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ABSTRACT 
 
PART II: TOWARD THE DEVELOPMENT OF A NOVEL ORALLY-AVAILABLE ASTHMA 
TREATMENT TARGETING GABAA RECEPTORS IN THE LUNGS 
by 
Olivia B. Yu 
The University of Wisconsin-Milwaukee, 2019 
Under the Supervision of Professor Alexander Arnold 
 
 
The treatment and control of asthma remains a persistent modern clinical problem, 
despite being recognized for decades and occurrence across the globe.10 The central hallmarks 
of asthma are chronically inflamed airways, hypersensitivity to certain external stimuli, and 
obstruction of the airways.11 These characteristics lead to clinical features that include persistent 
cough, shortness of breath, wheezing, coughing, and chest tightness.12 
Our laboratory, in collaboration with the Cook laboratory at UWM, is seeking an alternate 
therapy to combat multiple symptoms associated with living with acute asthma.1, 13 Currently 
available treatments have multiple factors that could be improved upon, from the imprecise 
dosages of treatment delivered via inhaler14 to the adverse side effects of systemically 
administered corticosteroids.15-19 A better asthma drug alternative would be orally administered 
to improve patient compliance and eliminate dosage irregularity. Furthermore, unwanted 
central nervous system effects should be avoided at all cost. Finally, the alternative drug should 
alleviate a full range of asthma symptoms, such as relaxing the smooth muscle constriction and 
decreasing inflammation in the airways, rendering combination treatments obsolete.20 
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Central to achieving those goals is a new therapeutic target for asthma, which is the 
family of gamma-aminobutyric acid A receptors (GABAAR). GABAARs are ligand-gated chloride ion 
channels, whose primary function is to regulate intracellular chloride concentrations, especially 
in neurons. The GABAARs consists of five subunits combined into a heteropentamer.21 In recent 
decades, the Cook group has introduced GABAAR ligands based on the imidazobenzodiazepine 
scaffold that are selective to certain subtypes of GABAARs.22 With recent confirmation that 
distinct populations of GABAAR subtypes are present in lung tissue, our collaboration is keen to 
develop molecules that can target these subtypes. Further investigations have shown that these 
ligands mediate distinct pharmacological properties including relaxation of airway smooth 
muscle and anti-inflammation. Proof of concept that GABAAR ligands can alleviate asthma 
symptoms was first shown with plant-based positive allosteric modulator honokiol by Munroe et 
al.23 Our group has since developed imidazobenzodiazepine-based compounds that target 
relevant GABAAR subtypes expressed in the lung with pronounced efficacy in several asthmatic 
mouse models.1, 13, 20, 24 Achieving targeted asthmatic relief with oral medication and thus 
eliminating the use of corticosteroids is seen as a significant step forward in asthma treatment. 
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PART I: AN INVESTIGATION OF CALCITROIC ACID AND ITS PHASE II CONJUGATES 
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1.1 A Brief History of Vitamin D 
 
 
The establishment of vitamins as essential to a complete diet is actually a surprisingly 
new discovery, made after the turn of the twentieth century. While certain diseases caused by 
vitamin-deficiency had already been discovered and were known to be treatable by 
supplementing one’s diet,25 the reasons behind the supplemental cures were unknown or 
incorrect at that time. The early 1900’s saw the discovery of the first few “vital amines,” or 
vitamins, in large part due to the work of Elmer McCollum. Following the 1910 demonstrations 
by both Hopkins26 and Funk27 that a diet consisting only of purified proteins, fats, salts, and 
carbohydrates was incapable of encouraging animal growth, McCollum isolated a lipophilic non-
saponifiable compound from butter fat which was found to be necessary for growth and 
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prevented xerophthalmia in rats in 1914.28 This “factor A” soon became known as vitamin A, and 
its discovery led to vitamin B’s discovery by McCollum (amongst others)29 only four years later.30  
At the same time, in the Industrial Revolution in England in the early twentieth century, 
cases of rickets, especially in children, had reached epidemic proportions as polluted air blocked 
the sun and people living in poverty worked long hours in factories.31 The discovery of the first 
vitamins led to administration of cod liver oil, a good source of vitamin A, but which also 
unbeknownst contained vitamins D and E as well. The treatment with cod liver oil cured rickets, 
but McCollum, doubting whether it was in fact vitamin A’s action, performed a groundbreaking 
study. He oxidized vitamin A in cod liver oil to destroy its activity, and found that even so it could 
be used to cure rickets (though not the vitamin A deficiency disease xerophthalmia).32 He thus 
concluded that there was another vital vitamin present in cod liver oil that cured rickets, and 
called this vitamin D,33 as it was the fourth vitamin to be discovered and named.  
In Europe, a discovery about curing rickets from a completely different source was made 
by both Huldschinsky34 and Chick et al.35 They independently showed that rickets could also be 
cured by exposing ricketic children to UV light. Therapeutic exposure to sunlight was no different 
than cod liver oil administration in curing the disease, providing the interesting insight that 
vitamin D has both vitamin-like and hormone-like properties.36 Steenbock, at Wisconsin, 
confirmed this in 1924 when he showed that he could induce vitamin D activity to cure rickets in 
lactating goats by irradiating both animals and diets with UV light. This showed that there was an 
inactive substance present that could be converted to an active form of vitamin D.  
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The isolation of vitamin D itself was initially in error, as Windaus in Germany accidentally first 
found a tachysterol/ergocalciferol adduct that was active against rickets and called it vitamin 
D1.37 Later, the true first isolation and structure determination of ergocalciferol (vitamin D2) was 
successfully conducted by Askew in Britain,38 which Windaus’ group later confirmed.39 Windaus 
and Bock went on in 1936 to isolate from skin 7-dehydrocholesterol, a precursor to vitamin D3, 
and convert it to cholecalciferol.40-41 Thereby the two nutritional forms of vitamin D were 
identified.  
It was not until 1967 that Hector DeLuca showed that radiolabeled vitamin D was not in 
fact the active form.42 Polar metabolites in target tissues caused the physiological response and 
were far more biologically active than unmetabolized vitamin D. In 1968, his group isolated the 
primary circulating form of vitamin D, the metabolite 25-hydroxyvitamin D3 (25(OH)D3), which 
was temporarily thought to be its most active form.43 However, DeLuca’s group later 
demonstrated indisputably that the yet more polar molecule 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3, trivial name calcitriol) was in fact the primary active form of vitamin D.44  
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1.2 The Structure and Function of the Vitamin D Receptor 
 
 
The vitamin D receptor (VDR) belongs to the superfamily of nuclear receptors and 
functions as a transcription factor. The receptor is responsible for the regulations of genes 
involved in calcium homeostasis, cell proliferation, and cell differentiation.45 While vitamin D was 
rapidly isolated in 1930,46 it took the field nearly 40 years to begin to discover that the 
metabolism of vitamin D was necessary to create biologically active molecules.42 This is due to 
their interactions with VDR: while VDR binds vitamin D metabolites and other molecules, the 
actual vitamin D2 and D3 molecules do not bind to the receptor.  
VDR was identified in 197347 and cloned fourteen years later.48 In 2000, the first portion 
of VDR’s three-dimensional structure was elucidated by X-ray crystallography: the ligand binding 
domain (LBD), responsible for binding small molecules. The ligand binding domain consists of 
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three β-sheets and three layers of 12 α-helices in sandwich folds (Figure 1a). It undergoes a 
major conformational change when a ligand is bound. Helix 11 shifts over and aligns with helix 
10, which allows helix 12 (pink) to swing shut to the position shown in Figure 1a and close off the 
binding pocket. Helix 12 is the “activating domain,” allowing the structure to stabilize by 
contributing to additional contacts with the ligand and overall making a more hydrophobic 
environment in the ligand pocket. Within the binding pocket, VDR’s native ligand calcitriol takes 
up only 56% of the cavity (blue mesh in Figure 1b). R274 and S278 from Helix 5, S237 from Helix 
3, Y143 from loop H1-H2, H305 from loop H6-H7, and H397 from Helix 11 form the anchoring 
hydrogen bonds that hold 1,25(OH)2D3 in the binding cavity (see Figure 1).49  
 To function as a transcription factor, VDR must in addition to binding small molecules 
also interact with cofactors, bind to activating DNA sequences, and take part in its heterodimer 
Figure 1: (a) The 12 α-helices of VDR represented as cylinders, with the activating domain helix shown in its closed position (pink) 
and its native ligand bound (yellow ball-and-stick). (b) The binding pocket cavity (blue mesh) and the anchoring interactions with 
surrounding residues that hold 1,25(OH)2D3 in the binding cavity. 
A B 
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with the retinoid X receptor (RXR). It thus has more than one domain (Figure 2). The A/B domain 
is at the N-terminus, and amongst nuclear receptors this domain is non-conserved as it is the 
part that binds various cofactors and enzymes.50 In VDR, this domain contains activating function 
1 (AF-1), which has some weak transcriptional activity in the absence of ligand.50  
The C domain, also known as the DNA binding domain, is highly conserved across nuclear 
receptors51 (Figure 3). It consists of 66 residues formed into two structures, both of which 
contain zinc finger motifs. The amino-terminal zinc finger region binds to the major groove of 
A/B            C            D                   
F A/B C D E 
AF-1 DBD LBD
AF-2 
Figure 2: A schematic and crystal structure outlining the general domains of a nuclear 
receptor. Structures adapted courtesy of the Protein Data Bank and Brzozowski AM, et.al.3 
Figure 3: Crystal structure of the DBDs of both VDR (left) and its typical heterodimer partner 
RXR (right) bound to their respective DNA hexameric half-sites.6 The light blue alpha helices 
in both structures bind to the major groove of the DNA. The Zn2+ ions taking part in 
coordination with cysteine residues are shown in gray. (PDB: 1YNW) 
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DNA at certain sequences called hormone response elements. The second zinc finger region is 
used to heterodimerize with other proteins.52-53 A typical hormone response element for the 
VDR-RXR heterodimer contains two hexameric half-sites with the sequence 5’-AGGTCA-3’ in a 
direct repeat with three neutral base pair spacers,54 compared to other half-site combinations 
for various nuclear receptors which can also involve inverted, everted, and mirror repeats. VDR 
response elements include those for many gene targets, such as CYP24A1, CYP3A4, SULT2A1, 
ABCB1, CYP2B6, CDKN1A, SPP1, OC, and OPN genes along with a host of others.55  
The D domain is simply the highly flexible hinge region that connects the DBD and the 
ligand binding domain (LBD), which is located in the E domain. The E domain is well-conserved 
and as the name implies is responsible for binding ligands. It consists of three β-sheets and 12 α-
helices in three layers of sandwich folds. This domain also interacts with coregulators 
(corepressors and coactivators) in a ligand dependent manner56 (Figure 4). When a ligand is 
Figure 4: A crystal stucture of the LBD of VDR. Within the binding pocket resides the 
calcitriol analogue VitIII 17-20Z (gray ball-and-stick). The short helical peptide in the upper 
left is the NR2 box of coactivator peptide DRIP 205 complexed to the LBD by way of the 
coactivator recognition sequence LxxLL. (PDB: 204J) 
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bound, a major conformational change occurs wherein Helix 12 swings shut over the binding 
pocket, stabilizing the structure through additional contacts with the ligand and creating a more 
hydrophobic environment in the binding pocket. Once helix 12 is in place, it provides a new 
exterior surface with a hydrophobic cleft and the two charged residues K246 and E420 on either 
end, forming a “charge clamp” with which coregulators and heterodimers interact.57  
This ability to regulate activity based on the presence of ligands, coactivators, and 
corepressors is known as the activating function 2 (AF-2) of the nuclear receptor: ligand 
dependent activity, as opposed to the ligand-independent activity of AF-1. The ligand-binding 
domain is thus the control center of VDR, regulating both DNA binding and transcription 
modification.58 Within the LBD is the essential ligand “cave” known as the activating function 2 
Figure 5: The flash-frozen RXR-VDR structure in complex with a DNA response element, as imaged by electron 
microscopy and overlaid with individual crystal structures.2 A) Side view shows the ligand binding domains of VDR 
(orange, facing) and RXR (green, far side) at ~90° angle from where they are bound to DNA. B) The DBDs encapsulate 
the response element DNA, the two recognition helices positioned at about 45° from each other due to the 3 base-pair 
spacer between the half-sites. Helix 12 is shown on VDR in red, in its closed position with ligands bound (shown in yellow 
for VDR; blue for RXR).  
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(AF-2) wherein binding with VDR’s many ligands occurs. Once a ligand has bound, AF-2 also 
completes the interface for binding with the retinoid X receptor as well as other coactivators and 
corepressors (Figure 5). When heterodimerized with the retinoid X receptor (VDR’s most 
common dimeric partner), the two bind sequences on DNA known as “vitamin D-responsive 
elements” (VDRE) on VDR target genes and recruit additional coactivators.59 
The specificity of the target binding sequences allows for promoter-selective gene 
transcription, and ultimately determines the rate of protein production via RNA polymerase II 
transcription. Once the VDR-RXR heterodimer is bound, additional coactivators are recruited 
including the RNA polymerase II and other transcriptional proteins with histone acetyl 
transferases activity to mediate priming and eventual transcription of DNA.60  
The F domain, which is entirely variable across nuclear receptors, is absent in VDR.61-62  
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1.3 The Phase I Metabolism of Vitamin D and Calcitroic Acid 
 
 
As noted previously, it took some time before scientists determined that it was not 
vitamin D2 or D3 that acted on the vitamin D receptor, but instead its metabolites. This work was 
pioneered in 1961 by Kodicek and Chalk with in vivo dosing of 14C-labeled vitamin D2 which 
showed that metabolism of 
the labeled vitamin was 
occurring.63 However, it 
was the administration of 
3H-labeled vitamin analogs 
in the 1960s that led to the 
first identification of a 
Figure 6: To identify metabolic products from 1,25(OH)2D3, the 14C and 3H analogues 
were administered. The resulting organ extracts contained an enriched 3H-labeled 
material, indicating modification to the side chain in calcitriol’s metabolites. 
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vitamin D analog with significant biological activity, 25(OH)D3.43 The same group also discovered 
the most active vitamin D analog known, 1,25(OH)2D3, in 1971.64 These discoveries initiated 
many research programs in the fields of medicine, biochemistry, physiology, chemistry, and 
pharmacology, especially once the vitamin D receptor was identified65 and eventually cloned.48  
A near miss to uncovering CTA occurred in 1965, when it was observed that significant 
radioactivity was present in the aqueous extracts of the bile and intestines of 1α-3H-D3 dosed 
rats; however, none of these radioactive species were analyzed further.66 With improvement in 
rat bile duct cannulation, the same group collected bile for 24 hours and separated it 
chromatographically into five fractions including “fraction D,” which after acid hydrolysis 
separated into polar and less polar fractions.67 A glucuronide conjugate of a vitamin D analog 
was identified as a major component, which masked CTA; however, separation methods for 
acidic metabolites such an anion-exchange chromatography and derivatization with 
diazomethane were established. Although researchers repeatedly reported large amounts of 
radioactivity for aqueous extracts of liver and intestine from 3H-25(OH)D3 treated animals,68 it 
would take another 10 years until the first isolation of CTA took place.7 In their study, rats were 
treated with a combination of 14C- and 3H- labeled 1,25(OH)2D3 (Figure 6) and after 4 hours, 
soluble contents of liver and intestine (with contents) were separated as a chloroform fraction 
and methanol/water fraction. The aqueous layers of both tissues were enriched in 3H over 14C, 
indicating that the side chain of 1,25(OH)2D3 was shortened during metabolism—a key finding. 
Fractions of negatively charged compounds after diethylaminoethyl cellulose separation (anion 
exchange) had especially significant amounts of radioactivity. 3H-CTA was then isolated as methyl 
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ester after esterification with diazomethane and characterized by mass spectrometry.7 Blood 
was found to contain a small amount of 3H-CTA; however, much larger amounts were found in 
the liver and especially in the intestine plus content. Thus, the hypothesis that CTA is part of the 
enterohepatic circulation was subsequently confirmed with the identification of 3H-CTA in the 
bile duct.8 A more detailed analysis of tissue distribution of CTA with the techniques stated 
above using bolus administration of 1,25(OH)2-[3α-3H]D3 demonstrated a more complex 
metabolism.69 Primarily, other acidic metabolites were found that were suggested to be polar 
CTA conjugates, and secondarily, CTA was found in the intestine of bile duct-cannulated rats, 
which suggests endogenous mucosal synthesis of CTA. In addition, only up to 50% of the 
radioactive material could be extracted from dried liver, another indication of complex 
metabolite formation.  
Scheme 1: The metabolism of various vitamin D metabolites and analogues to CTA. 
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Due to the attention that the organ chloroform extracts received, however, several less 
abundant metabolites were identified long before CTA, uncovering one of the most pronounced 
pathways for vitamin D metabolism. The first evidence of the 24-hydroxylation of vitamin D was 
found in the blood of [1,2-3H]D3-treated chicks, with the product initially believed to be 
21,25(OH)2D3,70 but later identified as 24,25(OH)2D3 in chick kidney homogenates.71 It was 
further discovered that 1,25(OH)2D3 increases the production of 24,25(OH)2D3, suggesting for 
the first time an upregulation of 24-hydoxylase (CYP24A1) by 1,25(OH)2D3.72 CYP24A1 was first 
identified in chick kidneys,73 and further characterization of the purified enzyme found in kidney 
mitochondria was accomplished by several groups74-75 and eventually led to cloning and 
expression of mitochondrial kidney CYP24A1.76  
In the meantime, several new vitamin D metabolites were identified in vivo or with 
perfused rat kidney: 24,25,26,27-tetranor-23(OH)D377 and 24,25,26,27-tetranor-1,23(OH)2D3,78 
which were assumed to be the most likely precursors for CTA (Scheme 1). The conversion of 
24,25,26,27-tetranor-1,23(OH)2D3 into CTA was then reported by two groups in the same year 
using perfused rat kidney.79-80 It had already been shown that cultured bone cells mediated the 
same metabolism in addition to the earlier reported conversion of 25-(OH)D3 to 24,25(OH)2D3.81 
As such, it was known that the expression of CYP24A1 was not limited to the kidney. Analysis of 
recombinant human CYP24A1 confirmed that a single P450 enzyme catalyzed the six-step 
pathway from 1,25(OH)2D3 to CTA,82 confirming the most pronounced CTA-generating route, the 
C-24 hydroxylation pathway. In addition, it was demonstrated that CYP24A1 also mediated the 
alternative C-23 hydroxylation pathway, a four-step monooxygenation from 25-(OH)D3 to 
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25(OH)D3-26,23-lactone, which interestingly was not observed for rat CYP24A1.83 Human 
recombinant CYP24A1 was also able to catalyze the conversion of 25(OH)D3 to 24,25,26,27-
tetranor-23(OH)D3;84 however complete oxidation to calcioic acid was only observed in perfused 
rat kidney.85 In addition, CTA was found in perfused kidney when treated with supplement-
derived 1,25(OH)2D2,86 although CYP24A1 seemed not to be the only enzyme involved in this 
process.87 CTA was also identified in the bile of rats treated with 1,25(OH)2D4.88 
Vitamin D analogs bearing an α1 hydroxyl functionality, such as 1,25(OH)2D3, bind more 
strongly to VDR compared to their non-1α-hydroxylated counterpart (such as 25(OH)D3) and are 
therefore biologically more active at the same concentration. The identification, purification, and 
characterization of the responsible enzyme, 25-hydroxyvitamin D3 1α-hydroxylase (CYP27B1), 
has been ongoing for five decades.89 Just as with CYP24A1, CYP27B1 expression is not limited to 
kidney mitochondria. Only recently was it shown that CYP27B1 is able to convert most vitamin D 
metabolites of the 24-hydroxylation pathway to their corresponding 1α-hydroxyl products; 
however, the conversion of 24,25,26,27-tetranor-23(OH)D3 to 24,25,26,27-tetranor-1,23(OH)2D3 
and calcioic acid to CTA have not been investigated yet.90  
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1.4 The Synthesis of Calcitroic Acid 
 
 
As these findings have shown, CTA is the most significant final metabolite of vitamin D. 
When CTA was discovered by DeLuca in 1974, however, it was quickly characterized and then 
mostly forgotten for forty years because it was 
believed that no specific biological activity was 
mediated by CTA. Recently, however, a study in 
our lab unexpectedly found CTA to be active in 
cells.4 For a VDR-mediated transcription assay, 
our group found VDR target gene CYP24A1 
upregulated in DU145 cells in the presence of 
CTA (Figure 7). The focus of this project has  
Figure 7: CYP24A1 gene regulation by VDR ligands (7.5 mM) in 
DU145 cells after 18 hrs. Stars represent 0.001 P < (***) 
compared to vehicle DMSO. Graph courtesy of Teske KA et al.4 
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Scheme 2: Synthesis of CTA starting from a cholesterol analogue precursor 
Scheme 3: Synthesis of CTA using a provitamin D precursor 
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thus been to evaluate the biological activity of CTA in order to assess its function. Unfortunately, 
CTA is not available commercially in the quantities required to study it fully, and is prohibitively 
expensive even in small amounts (~$4000/mg).  
The reason for the high price of CTA is that its isolation by both synthetic and enzymatic 
methods have very low overall yields. The first CTA synthesis was reported in 1981 (Scheme 2).91 
The acetoxy derivative of Fernholz acid, which is commercially available from Steraloids, was 
used as starting material and converted using an Arndt-Eistert reaction to the corresponding 
higher carboxy homologue. Allylic bromination and subsequent elimination installed the diene, 
which was converted in low yield under photochemical and thermal conditions to the methyl 
ester of calcioic acid. 1α-hydroxylation was achieved by synthesizing a cyclovitamin D derivative 
followed by allylic oxidation and cycloreversion with acetic acid. Hydrolysis gave CTA in an overall 
yield of 0.09%. The optical rotation was not given, but the corresponding methyl ester coeluted 
in HPLC with the derivatized material isolated from rat livers. Small improvements to this route 
increased the overall yield to 0.28%.92  
Two years later, a new route based on a previous synthesis of vitamin D analogs was 
reported with an overall yield of 0.36% (Scheme 3).93 The synthesis started with 5,6-
dihydroergosterol, which was used to prepare the corresponding aldehyde. The carbon chain 
elongation was carried out by a Wittig reaction followed by demethylation, oxidation, and 
esterification. A quinone-like structure was generated by oxidation, α-carbon bromination, and 
elimination, which was subsequently isomerized and reduced to the allylic alcohol. The diene 
and alcohol function were protected, followed by oxidation and subsequent deprotection. The 
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retro Diels−Alder reaction recreated the diene, and conversion of the ester to the acid enabled a 
selective reduction of the epoxide followed by esterification. Finally, the seco-steroid scaffold 
Scheme 4: Synthesis of CTA starting from vitamin D2 using a Ring A phosphine oxide synthon 
 
Scheme 5: Synthesis of CTA starting from a seco-steroid precursor  
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was produced by light and subsequent saponification, generating CTA in 0.36% overall yield. 
Importantly, the light-induced ring opening reaction reduced significantly the overall yield of 
both described methods.  
During the 1980s and 1990s, many different synthetic strategies were explored to 
generate other vitamin D analogs, which led to the availability of many new synthons for their 
synthesis.94 The carbon chain elongation using a seco-steroid as a starting material to produce 
CTA was introduced in 1990 (Scheme 4).95 The starting material was a seleno acetal, which was 
generated from the corresponding 1α-hydroxy vitamin D aldehyde derivative. Formylation gave a 
lithio-demethylseleno derivative as a carbon homologue, which was protected as a hetero 
Diels−Alder product with sulfur dioxide followed by radical deselenation induced by light. A retro 
Diels−Alder reaction was achieved under mild conditions followed by oxidation and esterification 
to the corresponding ester. Photoisomerization installed the natural Z-configuration of methyl 
ester of the protected CTA, which was subsequently deprotected and hydrolyzed to give CTA. 
The reactions described in Scheme 4 achieved high yields; however, the route has many steps if 
the synthesis of the precursor would be included.  
Very recently, a synthesis using commercially available chemicals was reported, that for 
the first time enabled the synthesis of gram quantities of CTA (Scheme 5).96 Originally developed 
to generate 13C-labeled CTA for metabolic research, this synthesis used the Inhoffen Lythgoe 
diol, which is both commercially available and readily synthesized from vitamin D2.97 This new 
route was the foundation for our CTA production, which we modified in several ways to improve 
reaction yields.  
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1.5 Synthetic Strategy for Production of Calcitroic Acid 
 
 
Synthesis of Inhoffen Lythgoe diol:98 
 
The Meyer synthesis used purchased Inhoffen Lythgoe diol.96 While we did initially 
purchase some diol, we quickly decided that it would be less expensive to produce the diol using 
ozonolysis from the much cheaper ergocalciferol (vitamin D2). We initially planned to use a 
H
OH
OH
OH
H
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reductive workup to isolate the aldehyde and convert it to the diol in a separate step. This 
proved difficult because the aldehyde was difficult to purify and the yield was low. After we 
learned from a collaborator that the reduction to the diol could be done in one-pot using sodium 
borohydride, we changed our route to a one-pot two-step reaction to generate the Inhoffen 
Lythgoe diol.   
Even so, perfecting this reaction 
was quite challenging. There were 
multiple issues, starting with finding the 
balance between enough MeOH to 
support the ozonolysis process and 
enough pyridine to dissolve 
ergocalciferol. We were also unable to 
get the reaction to reliably turn blue (saturate with O3) and needed to acquire a “fizzer” gas 
dispersion fitting to bubble O3 through the solution with high surface area, allowing it to 
saturate. Once those had been solved, there were additional issues realized as we attempted to 
scale the reaction up; namely, we were unsuccessful scaling it up past the 3 g scale. A specific 
round bottom flask (500mL, with a narrow outlet for used gas to escape) filled halfway was the 
only way to get a balance between enough solvent in the proper proportions to dissolve 3 g of 
vitamin D2, and having a large enough surface area-to-volume ratio to be able to keep the 
solution at —78°C so the ozone could saturate the solution. Running the reaction for a full 7 
hours at that temperature was generally the best way to ensure that all double bonds are 
Figure 8: Saturated with ozone, the MeOH/pyridine solution turns blue 
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oxidized. After allowing the reaction to warm up overnight, we added NaBH4 in tablet form one 
at a time to limit the surface area and ensure that the solution did not overheat. 
The workup remained a problematic issue for nearly the entire time that the diol was 
being produced. After evaporation of the methanol, we were left with a large amount of 
pyridine, which had been required to keep ergocalciferol in solution during the ozonolysis. We 
were not able to evaporate pyridine or use azeotropic distillation to remove it from the product. 
During the workup, the extracted DCM layer was washed multiple times with 1M HCl in an 
attempt to protonate pyridine and dissolve it in the aqueous layer. This worked somewhat, but 
still left plenty behind. Because pyridine and the diol were nearly overlapping via TLC plate, full 
separation was never achieved via flash chromatography. We resorted to dealing with its 
presence throughout the next step, until the tosylate protection rendered the product 
sufficiently nonpolar to enable separation via flash chromatography.  
However, on the final round of diol production, we used 10% CuSO4 for washing the 
organic layer. This single wash removed all pyridine from the organic layer. As such, it is highly 
recommended for eliminating pyridine in future syntheses. 
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Synthesis of O-silylated C,D-ring tosylate:  
 
The Meyer synthesis was followed for the 
protection of the two alcohol functions 
independently. The tosylate group on the primary 
alcohol was carried out first, as it is the more 
accessible alcohol. Thus, with one equivalent of 
Ts-Cl, the primary alcohol will be selectively 
protected in the presence of the secondary 
alcohol. This reaction was reliable and gave the tosylated C,D-ring in high yield. The silyl ether 
protecting group was added with a t-butyldimethylsilyl trifluoromethanesulfonate (TBSOTf). This 
protecting group is stable under weak acidic conditions, very stable under basic conditions and 
readily removed in the presence of fluorine ions.  
 
 
Figure 9: Concentrated doubly-protected C,D-ring takes on a 
slightly pink hue 
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Synthesis of O-silylated C,D-ring nitrile: 
 
The Meyer synthesis’ carbon elongation 
utilizes a classic route wherein the side chain’s 
tosylate is a good leaving group for substitution 
by potassium cyanide. In our lab, this reaction was 
challenging and unreliable from the start. The 
Meyer synthesis heated the reaction to 90°C, but 
we found that this heat was sufficient to lose a 
moderate portion of the product by loss of the 
silyl protecting group (20-60%), even if closely 
monitored and quenched as soon as the starting 
material was gone. Even reactions with minimal 
degradation faced a more severe problem: loss of 
product during workup. Initially, the reaction was 
carried out in DMSO—a necessary concession when dealing with organic compounds that need 
to react with inorganic salts (NaOH and KCN). For the workup, the reaction was dissolved in 10-
50x the volume of water and extracted with ethyl acetate, but it still resulted in a large amount 
OTBS
H
OTs
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H
N
Figure 10: Nitrile reaction turns red as we attempt to get 
salts into solution. When sonicated/heated, sometimes it 
turned green when everything was in solution 
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of DMSO in the organic layer. Excessive washing of the organic layer with water until the DMSO 
disappeared resulted in unacceptably low yields. This was observed across the many different 
workup procedures we tried, which included: extraction with many solvents, especially ones 
known not to dissolve DMSO very well; using an excessive amount of water to dilute DMSO; 
using a recursive extract/wash system with a series of separatory funnels to get progressively 
less DMSO and more organic product; using DMF instead of DMSO (similar problems) and using 
ACN instead of DMSO (no conversion).  
Unable to produce good results, we changed the method. ACN on its own was unable to 
solubilize the salts enough for the reaction to proceed at any temperature. However, a polar but 
volatile solvent would change the difficulty of this reaction workup entirely, so we tried another 
method: crown ethers. It is well-known that 18-crown-6 readily solubilizes K+ ions. While 
potassium wasn’t the ion of interest for purposes of substitution, the strong affinity of 18-crown-
6 for K+ causes the “naked ion” effect for CN—, wherein it becomes an even better nucleophile in 
the absence of its balancing cation. This altered reaction was highly successful when run at 75°C, 
with no trouble during the workup and an improved yield around 93%. 
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Synthesis of O-silylated C,D-ring aldehyde: 
 
The side-chain modification continues, converting the nitrile in three steps to the 
aldehyde, to the acid, and then to the ester. The reduction of the 
nitrile to the aldehyde was carried out with DIBAL in dry DCM at 0°C. 
During the quench it should be noted that the reaction needs to be 
kept at 0°C throughout. The addition of aqueous NH4Cl to quench the 
DIBAL is extremely exothermic and prone to bubbling over, especially 
during the first few drops. We found that the quenched reaction does 
need to stir for at least a half hour before breaking up the viscous 
solution with t-butyl methyl ether (TBME). Once TBME was added, the reaction needed to stir at 
0°C for as long as necessary until the aqueous layer separated more thoroughly, forming a white 
fluffy gelatin that typically balled up and adhered to the flask somewhere (Figure 11). Rushing 
these steps results in loss of product, possibly because intermediate imines are not fully 
hydrolyzed to the aldehyde. Only then is it appropriate to begin drying off the aqueous layer, 
which is done simply by adding a large amount of MgSO4 until a dry solution is achieved. 
Breaking up the solidified MgSO4 as best as possible is advised in order to allow any product 
trapped within the gelatin to dissolve into the organic layer. Because the nitrile and aldehyde are 
Figure 11: Fluffy quenched DIBAL 
following aq. NH4Cl addition and 
TBME dilution is ready for drying 
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almost overlapping via TLC, it is important that this reaction run to completion before it is 
quenched; otherwise separation between the two is impossible by chromatography.  
In the case that the 13C labeling will not lead to a compound distinguishable by MS from 
non-labeled CTA, a secondary plan to label the compound with an 18O during this step is 
proposed. In this reaction, DIBAL reacts with the nitrile to form an intermediate imine. The 
intermediate imine is hydrolyzed by water to form an aldehyde, acquiring the oxygen molecule 
from the water. As such, quenching the reaction using 18O heavy water would add another label 
to the final product.  
 
 
Synthesis of O-silylated C,D-ring acid: 
The conversion of the aldehyde to the acid is a 
Pinnick oxidation. In this reaction, chlorous acid is 
formed from chlorite under acidic conditions as the 
oxidant. Chlorous acid adds to the aldehyde and then 
undergoes pericyclic fragmentation to produce the acid 
function and hypochlorous acid (HOCl). The presence of Figure 12: Faintly seen aqueous and organic layers 
as reaction turns yellow in Pinnick oxidation 
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the HOCl scavenger 2-methyl-2-butene then ensures that the species will not go on to destroy 
other NaClO2 ions (which would prevent them from completing the oxidation) or produce other 
unwanted byproducts.99 This reaction is a little unusual in that it uses mixed aqueous and organic 
phases. The starting material is dissolved in t-butanol, with the 2-methyl-2-butene hypochlorous 
acid byproduct scavenger added. The NaClO2 is then dissolved separately in water containing the 
stabilizer/buffer NaH2PO4. The water layer is then added to the organic, and a yellow-green 
solution is immediately observed. The color fades as the reaction proceeds. While this reaction 
can be separated via chromatography, we found that all byproducts were easily removed during 
the workup: upon extraction, NaH2PO4, NaClO2, HOCl and its scavenger byproduct went into the 
aqueous layer while t-butanol and 2-methyl-2-butene were removed through concentration. 
Thus, by proceeding directly to the next reaction, we returned higher yields. 
 
 
Synthesis of O-silylated C,D-ring ester: 
For the esterification, the methylating agent 
trimethylsilyldiazomethane was used, which was added dropwise through 
a septum into the dry toluene/MeOH reaction mixture. The mixture turns 
Figure 13: Trimethylsilyldiazo-
methane turns the methylating 
reaction yellow 
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yellow to indicate the presence of the diazo compound, and when complete it can be quenched 
with acetic acid, turning the solution clear again. The solution is then concentrated and purified 
directly via column (quantitative yield).  
 
 
Synthesis of C,D-ring alcohol: 
 
The reaction to deprotect the silyl group to an alcohol group using TFA worked fine 
during the first rounds of synthesis. However, when we were reacting more material, a 
previously trace byproduct spot took over about half of the reaction yield. While we were unable 
to identify this byproduct, we inadvertently discovered how to convert it to the desired C,D-
alcohol product. We separated the desired deprotected alcohol product from the rest of the 
crude (which contained both unreacted silyl-protected C,D-ring alcohol and the unknown 
byproduct). The crude was then re-reacted with TBAF, anticipating that what remained 
unreacted would instead form product, and the byproduct would just be a loss. Instead, we saw 
the byproduct spot disappear to form the desired C,D-ring alcohol product, while the unreacted 
starting material remained untouched. Continued reactions made clear that this was the best 
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way to manage the large amount of byproduct that formed: first, the reaction was run with TFA 
to form both anticipated product and byproduct, and then a second reaction was run to convert 
the byproduct to the anticipated product. Eventually, all the silyl-protected substrate was 
converted to the alcohol in an overall improved yield across the two reactions (89%). 
 
 
Synthesis of C,D-ring ketone: 
Following the Meyer synthesis again, we then 
oxidized the alcohol to the ketone. The reaction is best run 
under nitrogen at room temperature and proceeds fairly 
well as long as the DCM is dry. It is important for the PDC to 
be very freshly ground prior to the reaction to expose the 
unoxidized surface, which is orange instead of brown or 
black. As PDC does not dissolve in DCM, a suspension will 
form that turns black as the reaction proceeds. The reaction 
appears to be complete within 3 hours, but it is best to run overnight to ensure complete 
conversion, as both starting material and product have the same Rf and thus cannot be 
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Figure 14: Finely ground, oxidized PDC 
turning black during the reaction 
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separated by chromatography. Completion can be confirmed by NMR. It is important to remove 
all product off the solid PDC. Filtering over celite, then re-suspending the solids in fresh DCM 
with vigorous stirring at least three more times led to improved yields (up to 20% improvement).  
 
Synthesis of O-Bis-silylated calcitroic acid methyl ester: 
The Wittig-Horner ligation was the most challenging reaction in the synthesis of CTA, and 
prone to failure and low yields. Successful, moderate-yield reactions required extensive planning, 
careful controlled execution, and extremely dry conditions. To begin with, solid ketone and solid 
commercially-acquired organophosphine oxide (ring A synthon) ligand were never dry enough to 
use because transferring them brings them in contact with air, and the solid can trap water. 
Instead, they needed to be dissolved in THF and dried overnight in small, oven-dried flasks with 
molecular sieves. The glassware setup needed to be oven dried overnight and assembled in its 
entirety while hot (including dropping funnel, molecular sieves in both RBF and funnel, and stir 
bar), then vacuum and nitrogen purged multiple times as it cooled. Once set, it must remain 
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under nitrogen and cannot be opened to air; instead, a dropping funnel and syringes were used 
to transfer/add the reagents.  
 
During the first stage, the phosphine oxide solution was added to the 3-neck RBF from 
the side neck and the solution was cooled to —78°C. N-butyl lithium was added via syringe 
through the side neck, and a brilliant red color resulted. This color is the main indication of 
success in the reaction, as its loss indicates that the reaction is exposed to water or that 
unreacted n-BuLi attacked the ketone (1,2 addition) instead of deprotonating the phosphine 
oxide. While the molar ratio of the n-BuLi must be higher than that of the ketone being added, it 
must be lower than that of the phosphine oxide it is deprotonating (recommended 1:1.5 or 
greater). After an hour of stirring, the reaction was briefly suspended above the dry ice bath, 
allowing it to reach a higher temperature and ensure full consumption of the n-BuLi. The color 
darkened to deep blood red (see Figure 15). The reaction was then cooled again to —78°C. In 
the second phase, the ketone was added from the dropping funnel. This needed to be done very 
Figure 15: Wittig-Horner reaction at different stages. From left to right: the deprotonation of organophosphine oxide 
by n-BuLi; reaction color darkened upon brief removal from dry ice bath to ensure full consumption of n-BuLi; an 
unsuccessful reaction turned peach color when quenched by water. 
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slowly to ensure that the reaction does not warm up significantly. Also, careful monitoring of the 
color of the solution was necessary. If the reaction started to lose its color, and especially if a 
quick conversion to yellow was seen, the reaction was aborted immediately and no more ketone 
was added. Any ketone that had already been added could not be recovered due to 1,2-addition 
by the n-BuLi, so watching this step carefully was imperative. The reaction could then be 
monitored by TLC, but samples could only be extracted via syringe, as opening the reaction 
results in noteworthy product loss. The reaction ran for up to 5 hours, then was quenched with 
water and warmed to room temperature for work-up. The quenched reaction was extracted 
with TBME, the extract washed with brine, concentrated and purified by column 
chromatography (78% yield).  
 
 
Synthesis of calcitroic acid methyl ester:  
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The subsequent TBAF deprotection of the A-ring synthon’s silyl ethers needs to be kept 
very dry and uses ten equivalents of TBAF in order to get excellent yields. This reaction was the 
highest-yielding option for small reactions. However, for large reactions TBA was difficult to 
separate from the product. Generally speaking, formation of the TBA-Cl salt using NH4Cl washes 
dissolves TBA in the water layer. In practice, even an excessive number of washes does not fully 
remove TBA from the organic layer. This was okay for small reactions, where the TBA would then 
be separated via column chromatography, but in larger batches there was far too much leftover 
TBA even after extraction, and it co-eluted with the product. This problem is bypassed by instead 
using camphorsulfonic acid (CSA) as a convenient, speedy alternative, requiring only about 15 
minutes of reaction and yielding a very clean product after workup. Because of this, the CSA 
product could be used in the next step without purification, but the yield across the two 
reactions when we used CSA was never as high as the yield when we used TBAF. 
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Synthesis of calcitroic acid: 
The final reaction of the CTA synthesis is the hydrolysis from the methyl ester to the acid. 
This synthesis had been previously reported using KOH at 60°C for 1.5 hours. When we struggled 
to carry out this reaction, we tried several alternate hydrolysis options. We discovered that using 
room temperature and NaOH resulted in better yields (84% compared to 74%) and avoided the 
compound degradation that we had been seeing at elevated temperatures.  
 
 
 
Discussion 
 
Overall, the Meyer group reported a yield of 12.8% for CTA. This is an impressive 
improvement over the 0.36% reported earlier. Our improved synthesis starting from the 
Inhoffen Lythgoe diol had an overall 29% yield. While it was more cost-effective in our lab to 
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start from ergocalciferol rather than purchasing the diol, the low yield (57%) of the initial 
ozonolysis and reduction steps decreased the yield for all 13 steps to 16%. Using K13CN to 
substitute a labeled carbon as outlined by Meyer also afforded the 13C-labeled CTA in the same 
yield. As an alternate product, the same method was utilized to generate the vitamin D 
metabolic product calcioic acid: the corresponding A-ring synthon is commercially available and 
afforded the corresponding O-silylated calcioic acid methyl ester in comparable yields. Using our 
variation of the Meyer synthetic method, a total of 3.2g of CTA was able to be generated. This 
material was used to both characterize CTA, provide the substance to various collaborators, and 
as a scaffold from which to synthesize a variety of secondary metabolic products for CTA. 
 
 
1. Lacroix, J.-F. Design and Synthesis of A-ring/seco-B-ring vitamin D analogues. McGill 
University, 2012. 
2. Meyer, D.; Rentsch, L.; Marti, R., Efficient and scalable total synthesis of calcitroic acid  
and its 13C-labeled derivative. RSC Advances 2014, 4 (61), 32327-32334. 
3. Kürti, L. Czakó, B., Pinnick Oxidation. In Strategic applications of named reactions in 
organic synthesis: background and detailed mechanisms, Elsevier: 2005; pp 354-356. 
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1.6 Characterization of Calcitroic Acid Synthesis Compounds 
 
 
Ergocalciferol was purchased from variable commercial sources (Alfa Aesar J62163, 
AstaTech 44109, Research Products International C20300, Sigma-Aldrich 95220, VWR 101172-
472). Both of the phosphine oxides were purchased from ChemScene (CS-M1835, CS-M0003). All 
moisture or oxygen-sensitive reactions were carried out under a dry nitrogen atmosphere. 
Reaction temperatures refer to the containing bath temperatures. Reactions were monitored by 
thin-layer chromatography (TLC) using Merck 60 UV254 silica gel plates (Sigma-Aldrich). 
Visualization was performed with UV light, cerium molybdate general stain followed by heating, 
and other methods as noted. Synthesized compounds were purified by normal phase flash 
chromatography (SPI Biotage, silica gel 230-400 mesh) except where noted. Compound 
characterization was performed via Shimadzu 2020 LC-MS (single quadrupole) instrument. NMR 
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spectra were recorded on a Bruker Avance 500MHz instrument with compounds dissolved in the 
specified deuterated solvent. Optical rotations were recorded using Jasco DIP-370 Digital 
Polarimeter instrument in LCMS grade chloroform or methanol. 
 
Inhoffen-Lythgoe diol: Ergocalciferol (3g, 7.5mmol) was dissolved first in 
dry pyridine (7mL), and then that mixture was diluted in dry methanol 
(250mL). The 500mL RBF used was single-necked with a diffuse bubbler as 
the inlet for ozone and a slim outlet for the dissipating gas. The reaction 
mixture was cooled to -78°C and ozone was bubbled through it for 4-6 hours using an A2Z Ozone 
A2ZZ-5G 110 V with 38g/m3 O3 output. The reaction was monitored by TLC (UV and cerium 
molybdate). Many spots occur initially, which reduce to three main spots after several hours. 
One of the two lower spots, partially overlapping with the pyridine spot (Rf 0.10 EtOAc:Hex 1:3) 
is the product. When no more change was apparent after an additional hour of ozonolysis, the 
reaction mixture was then brought to 0°C and stirred vigorously. Sodium borohydride (2g, 
53mmol) was added carefully. Once fully dissolved, the reaction was quenched with 70mL of 
water and stirred for 5 minutes before concentrating. The crude reaction mixture was diluted 
with 100mL of water and extracted with DCM (3x100mL). The organic layers were washed with 
5% CuSO4 solution (100mL), 1M HCl (2x100mL) and saturated NaHCO3 (100mL), dried over 
MgSO4, concentrated, and purified by column chromatography (EtOAc:Hex 1:3) to yield the 
Inhoffen Lythgoe diol as a white solid (450mg, 57%). Note that this reaction could not be scaled 
up, as larger percentages of pyridine were not tolerated and larger reaction vessels could not be 
OH
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adequately cooled in order to allow ozone saturation. Rf 0.09 (EtOAc: Hex 1:3); 1H-NMR 
(500MHz, CDCl3) δ 0.97 (s, 3H), 1.04 (d, J = 5.0, 3H), 1.14-1.23 (m, 2H), 1.31-1.40 (m, 2H), 1.41-
1.53 (m, 5H), 1.54-1.62 (m, 2H), 1.78-1.91 (m, 3H), 1.98-2.04 (m, 1H), 3.38 (dd, J = 5.0, 3.5 Hz, 
1H), 3.65 (dd, J = 10, 3.0 Hz, 1H), 4.10 (d, J = 2.0, 1H); 13C-NMR: (125MHz, CDCl3) δ 13.6, 16.6, 
17.4, 22.6, 26.7, 33.5, 38.2, 40.2, 41.8, 52.4, 53.0, 67.6, 69.2; m/z calculated for C13H24O2 211 [M 
— H],— found 211; [𝛼]𝐷
25 = + 24.0 (c 1.0, CHCl3) 
 
C,D-ring tosylate: To a stirred solution of Inhoffen-Lythgoe diol (0.38g, 
1.78mmol) in dry DCM (20mL) was added 4-dimethylaminopyridine 
(DMAP; 0.44g, 3.58mmol) and p-toluenesulfonyl chloride (0.36g, 
1.88mmol). The reaction was stirred overnight at room temperature, then quenched with 1 M 
HCl (20mL). The reaction mixture was extracted with DCM (3x50mL) and combined organic 
layers were washed with water (50mL), dried over MgSO4, and purified by column 
chromatography (EtOAc:Hex 3:7) to yield C,D-ring tosylate as a white crystalline solid (410mg, 
84%); Rf 0.23 (EtOAc: Hex 1:3); 1H-NMR (500MHz, CDCl3) δ 0.92 (s, 3H), 1.00 (d, J = 5.0 Hz, 3H), 
1.13-1.26 (m, 4H), 1.31-1.38 (m, 1H), 1.42-1.51 (m, 3H), 1.52-1.62 (m, 1H), 1.66-1.75 (m, 2H), 
1.77-1.88 (m, 2H), 1.92-1.98 (m, 1H), 2.48 (s, 3H), 3.84 (dd, J = 6.5, 3.0 Hz, 1H), 3.98 (dd, J = 6.2, 
3.0 Hz, 1H), 4.10 (s, 1H), 7.38 (d, J = 8.4 Hz, 2H), 7.82 (d, J = 8.5 Hz, 2H); 13C-NMR: (125MHz, 
CDCl3) δ 13.49, 16.75, 17.35, 21.65, 22.46, 26.42, 33.56, 40.06, 41.88, 52.25, 52.26, 69.06, 75.61, 
127.92 (2C), 129.79 (2C), 133.10, 144.64; m/z calculated for C20H30O4S 430 [M + Na + ACN],+ 
found 430; [𝛼]𝐷
25 = + 19.0 (c 1.0, CHCl3) 
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O-silylated C,D-ring tosylate: To a solution of C,D-ring tosylate (0.40g, 
1.09mmol) in dry DCM (2mL) at 0°C was added 2,6-lutidine (0.15mL, 
1.31mmol) and tert-butyl dimethylsilyl trifluoromethanesulfonate 
(0.35mL, 1.53mmol). The reaction was monitored by TLC until completion 
(2 hours) and quenched with water (2mL). The crude mixture was extracted with DCM (3x15mL), 
washed with water (15mL), dried over MgSO4, concentrated, and purified by column 
chromatography (EtOAc : Hex 1:19) to yield O-silylated C,D-ring tosylate as a clear or slightly pink 
oil, which solidified during storage (0.32g, 62%); Rf 0.43 (EtOAc: Hex 1:19); 1H-NMR (500MHz, 
CDCl3) δ 0.00 (s, 3H), 0.02 (s, 3H), 0.88 (s, 3H), 0.89 (s, 9H), 0.97 (d, J = 6.5, 3H), 1.08-1.19 (m, 
3H), 1.19-1.26 (m, 1H), 1.26-1.42 (m, 3H), 1.49-1.57 (m, 1H), 1.58-1.71 (m, 3H), 1.73-1.84 (m, 
1H), 1.86-1.92 (m, 1H), 2.47 (s, 3H), 3.82 (dd, J = 6.5, 2.8 Hz, 1H), 3.95-4.02 (m, 2H), 7.36 (d, J = 
8.0 Hz, 2H), 7.80 (d, J = 10.2 Hz, 2H); 13C-NMR: (125MHz, CDCl3) δ –5.2, –4.8, 13.7, 16.8, 17.6, 
18.0, 21.6, 23.0, 25.8 (4C), 26.5, 34.3, 35.8, 40.4, 42.2, 52.4, 52.7, 69.2, 75.8, 127.9 (2C), 129.8 
(2C), 133.2, 144.6; m/z calculated for C26H48O4NSSi 499 [M + NH4],+ found 499; m/z calculated for 
C28H47O4NSSiNa 544 [M + Na + ACN],+ found 544; [𝛼]𝐷
25 = + 34.0 (c 1.0, CHCl3) 
 
 O-silylated C,D-ring nitrile: To a solution of O-silylated C,D-ring tosylate 
(2.74 g, 5.70 mmol) in dry acetonitrile (75mL) was added NaOH (0.46 g, 
11.40mmol), potassium cyanide (0.74g, 11.40mmol), and 18-crown-6 
(3.77g, 14.25mmol). The solution was stirred at 75°C for 2.5 hours or until 
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the starting material disappeared by TLC. Acetonitrile was removed under reduced pressure and 
the residue was dissolved in water (20mL) and extracted with EtOAc (3 x 20mL). The combined 
organic layers were washed with brine, dried over MgSO4, concentrated, and purified by column 
chromatography (EtOAc : Hex 3 : 97) to yield the O-silylated C,D-ring nitrile (1.80g, 94%) as a 
clear oil; Rf 0.20 (EtOAc: Hex 3:97); 1H-NMR (500MHz, CDCl3) δ 0.02 (s, 3H), 0.04 (s, 3H), 0.91 (s, 
9H), 0.95 (s, 3H), 1.16 (d, J = 6.6Hz, 3H), 1.18-1.29 (m, 3H), 1.30-1.36 (m, 1H), 1.37-1.46 (m, 3H), 
1.56-1.66 (m, 1H), 1.67-1.73 (m, 1H), 1.75-1.88 (m, 3H), 1.92-1.97 (m, 1H), 2.25 (dd, J = 16.6, 7.0 
Hz, 1H), 2.36 (dd, J = 16.6, 3.8 Hz, 1H), 4.01-4.04 (m, 1H); 13C-NMR: (125MHz, CDCl3) δ –5.2, –4.8, 
13.9, 17.5, 18.0, 19.3, 22.9, 24.7, 25.8 (3C), 27.2, 33.1, 34.2, 40.3, 42.2, 52.9, 55.4, 69.2, 119.1; 
m/z calculated for C20H41N2OSi 354 [M + NH4],+ found 354; [𝛼]𝐷
25 = + 48.0 (c 1.0, CHCl3) 
 
 O-silylated C,D-ring aldehyde: To a stirred solution of O-silylated C,D-ring 
nitrile (0.69g, 2.06mmol) in 20mL dry DCM at 0°C was added a solution of 
DIBAL (1.5 M in toluene, 4.80mL, 7.19mmol) dropwise. The reaction was 
monitored at 0°C for 45 minutes until complete by TLC. The reaction was 
then carefully quenched with 10mL of a saturated solution of NH4Cl (aq) and stirred for an hour 
at 0°C. The viscous solution was then broken up by stirring in TBME (60mL), which was kept at 
0°C for another two hours and then allowed to warm up overnight. The aqueous layer formed a 
fluffy white ball, which was dried off directly with MgSO4 and filtered. The organic filtrate was 
concentrated under reduced pressure and purified via column chromatography (EtOAc : hexanes 
5 : 95) to yield the O-silylated C,D-ring aldehyde (0.66g, 94%) as a clear oil: (Rf 0.41 (EtOAc: Hex 
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7:93); 1H-NMR (500MHz, CDCl3) δ 0.02 (s, 3H), 0.04 (s, 3H), 0.91 (s, 9H), 0.98 (s, 3H), 1.02 (d, J = 
6.5 Hz, 3H), 1.12-1.19 (m, 2H), 1.23-1.30 (m, 2H), 1.36-1.43 (m, 3H), 1.56-1.65 (m, 1H), 1.67-1.73 
(m, 1H), 1.76-1.86 (m, 2H), 1.94-2.00 (m, 1H), 2.02-2.09 (m, 1H), 2.13-2.19 (m, 1H), 2.47 (dd, J = 
15.7, 2.5 Hz, 1H), 4.01-4.04 (m, 1H), 9.70 (dd, J = 3.6, 1.4 Hz, 1H); 13C-NMR: (125MHz, CDCl3) δ –
5.2, –4.8, 13.7, 17.6, 18.0, 20.0, 23.0, 25.8 (3C), 27.6, 31.3, 34.3, 40.6, 42.3, 50.8, 53.0, 56.6, 
69.3, 203.7; m/z calculated for C20H41N2OSi 354 [M + NH4],+ found 354; [𝛼]𝐷
25 = + 27.0 (c 1.0, 
CHCl3) 
  
 O-silylated C,D-ring acid: Sodium phosphate monobasic monohydride 
(3.39g, 24.55mmol) was dissolved in 32mL of H2O. To this was added 
sodium chlorite (3.41g, 37.65mmol). The aqueous solution was then 
added to a stirred solution of O-silylated C,D-ring aldehyde (1.39g, 
4.09mmol) in tert-butanol (77mL) and 2-methyl-2-butene (19mL). The reaction was monitored 
for 1 hour until completion and then concentrated under reduced pressure. The residue was 
dissolved in H2O and extracted with DCM (3x50mL). The organic layers were washed with water 
(20mL), dried over MgSO4 and concentrated to the O-silylated C,D-ring acid (3.2g, 99%) as a 
white powder: Rf 0.19 (EtOAc: Hex 1:4); 1H-NMR (500MHz, CDCl3) δ 0.02 (s, 3H), 0.03 (s, 3H), 
0.91 (s, 9H), 0.97 (s, 3H), 1.03 (d, J = 6.4 Hz, 3H), 1.08-1.19 (m, 2H), 1.25-1.31 (m, 2H), 1.33-1.42 
(m, 3H), 1.55-1.65 (m, 1H), 1.66-1.72 (m, 1H), 1.77-1.88 (m, 2H), 1.91-2.08 (m, 3H), 2.49 (d, J = 
14.8, 3.2 Hz, 1H), 4.01-4.04 (m, 1H), 11.05 (bs, 1H); 13C-NMR: (125MHz, CDCl3) δ –5.2, –4.8, 13.7, 
17.6, 18.0, 19.5, 23.0, 25.8 (3C), 27.3, 33.2, 34.4, 40.6, 41.2, 42.3, 53.0, 56.5, 69.4, 179.7; m/z 
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calculated for C20H38O3Si 356 [M + H]+ , found 356; m/z calculated for C20H38O3Si 353 [M — H],— 
found 353; [𝛼]𝐷
25 = + 41.0 (c 1.0, CHCl3) 
 
O-silylated C,D-ring methyl ester: To a stirred solution of O-silylated C,D-
ring acid (1.01g, 2.86mmol) in 16.5mL toluene and 11mL MeOH was 
added trimethylsilyl diazomethane (2.12mL, 2M in diethyl ether, 
4.23mmol). The reaction was stirred for 1.5 hours at room temperature 
and then quenched with acetic acid. The mixture was concentrated under reduced pressure and 
purified by column chromatography (EtOAc : hexanes 3 : 97) to yield the O-silylated C,D-ring 
ester (1.05g, quantitative) as a clear oil: Rf 0.28 (EtOAc: Hex 3:97); 1H-NMR (500MHz, CDCl3) δ 
0.01 (s, 3H), 0.02 (s, 3H), 0.90 (s, 9H), 0.95-0.98 (m, 6H), 1.06-1.17 (m, 2H), 1.24-1.30 (m, 2H), 
1.33-1.49 (m, 3H), 1.54-1.64 (m, 1H), 1.65-1.71 (m, 1H), 1.74-1.87 (m, 2H), 1.89-2.03 (m, 3H), 
2.43 (dd, J = 14.2, 3.1 Hz, 1H), 3.67 (s, 3H), 3.99-4.03 (m, 1H); 13C-NMR: (125MHz, CDCl3) δ –5.2, 
–4.8, 13.8, 17.6, 18.0, 19.5, 23.0, 25.8 (3C), 27.3, 33.4, 34.4, 40.6, 41.3, 42.2, 51.3, 53.0, 56.6, 
69.4, 174.0; m/z calculated for C21H39O3Si 367 [M — H],— found 367; [𝛼]𝐷
25 = + 41.0 (c 1.0, CHCl3) 
 
  Methyl esterified C,D-ring alcohol: To a stirred solution of O-silylated 
C,D-ring ester (1.48g, 4.01mmol) in dry DCM (45mL) at 0°C was added 
trifluoroacetic acid (4.5mL, 58.4mmol). The reaction was stirred at 0°C for 
1.5 hours until it was complete by TLC. The reaction mixture was 
concentrated under reduced pressure and purified by column chromatography (EtOAc : hexanes 
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1 : 4)  to yield the esterified C,D-ring alcohol (0.93g, 91%) as a clear oil: Rf 0.32 (EtOAc: hexanes 
1:4); 1H-NMR (500MHz, CDCl3) δ 0.96-1.00 (m, 6H), 1.09-1.21 (m, 2H), 1.29-1.40 (m, 3H), 1.40-
1.53 (m, 3H), 1.55-1.65 (m, 1H), 1.78-1.89 (m, 3H), 1.89-1.97 (m, 1H), 1.97-2.05 (m, 2H), 2.44 
(dd, J = 14.2, 3.2 Hz, 1H), 3.68 (s, 3H), 4.08-4.11 (m, 1H); 13C-NMR: (125MHz, CDCl3) δ 13.6, 17.4, 
19.4, 22.5, 27.2, 33.4, 33.6, 40.3, 41.3, 42.0, 51.4, 52.6, 56.4, 69.2, 174.0; m/z calculated for 
C16H27O5 299 [M + FA — H],— found 299; C17H26O5F3 367 [M + TFA — H],— found 367; [𝛼]𝐷
25 = + 
30.0 (c 1.0, CHCl3) 
 
  Methyl esterified C,D-ring ketone: To a stirred solution of C,D-ring alcohol 
(0.653g, 2.57mmol) in dry DCM (50mL) was added freshly ground PDC 
(1.93g, 5.13mmol). The reaction was monitored for two hours at room 
temperature, then diluted with TBME (50mL) and filtered over celite. The 
filtered solid was resuspended twice more in fresh DCM (2x25mL) and stirred vigorously for a 
half hour each before being filtered again. The combined filtrates were concentrated under 
reduced pressure and purified via column chromatography (EtOAc : hexanes 1 : 4) to yield the 
C,D-ring ketone (0.565g, 87%) as a white solid: Rf 0.35 (EtOAc: Hex 1:4); 1H-NMR (500MHz, 
CDCl3) δ 0.63 (s, 3H), 0.98 (d, J = 6.5, 3H), 1.26-1.36 (m, 1H), 1.42-1.60 (m, 3H), 1.66-1.76 (m, 
1H), 1.78-1.93 (m, 3H), 1.94-2.04 (m, 2H), 2.04-2.09 (m, 1H), 2.14-2.27 (m, 2H), 2.36-2.46 (m, 
2H), 3.62 (s, 3H); 13C-NMR: (125MHz, CDCl3) δ 12.5, 19.0, 19.5, 23.9, 27.4, 33.3, 38.8, 40.8, 41.0, 
49.8, 51.4, 56.2, 61.8, 173.5, 211.5; m/z calculated for C15H24O3 253.1798 [M + H]+, found 
253.1766; [𝛼]𝐷
25 = — 5.0 (c 1.0, CHCl3) 
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O-Bis-silylated calcitroic acid methyl ester: A solution of n-
butyllithium (1.6 M in hexanes, 1.56mL, 2.50mmol) was added 
dropwise to a solution of the CTA A-ring phosphine oxide 
(1.84g, 3.16mmol, dried over 3Å molecular sieves  in  5 ml THF 
overnight) at —78°C in the presence of freshly dried 3Å 
molecular sieves. The solution turned deep red and was stirred for an hour at —78°C. Raising the 
solution out of the bath briefly deepened the red color and ensured that the deprotonation was 
complete. The solution was returned to the bath and C,D-ring ketone (0.42g, 1.66mmol, dried 
over 3Å molecular sieves in 5 ml THF overnight) was added dropwise. The solution was stirred 
for 5 hours at -78°C and then allowed to come to room temperature. The reaction mixture was 
then quenched with 10mL water, diluted with TBME, and extracted (TBME, 2x50mL). Combined 
organic layers were washed with brine, dried over MgSO4, and concentrated. The crude product 
was purified by column chromatography (EtoAc: Hex 5:95) to yield O-Bis-silylated CTA methyl 
ester (0.66g, 65%) as a viscous white oil; Rf 0.22 (EtOAc:Hex 3:97); 1H-NMR (500MHz, CDCl3) δ 
0.04-0.10 (m, 12H), 0.58 (s, 3H), 0.89 (s, 18H), 1.00 (d, J = 6.3 Hz, 3H), 1.26-1.36 (m, 3H), 1.46-
1.61 (m, 3H), 1.61-1.73 (m, 2H), 1.73-1.81 (m, 1H), 1.81-1.96 (m, 3H), 1.96-2.05 (m, 3H), 2.22 
(dd, J = 12.6, 7.6 Hz, 1H), 2.40-2.48 (m, 2H), 2.80-2.86 (m, 1H), 3.66 (s, 3H), 4.17-4.23 (m, 1H), 
4.35-4.40 (m, 1H), 4.84-4.89 (m, 1H), 5.16-5.20 (m, 1H), 6.03 (d, J = 11.2 Hz, 1H), 6.24 (d, J = 11.2 
Hz, 1H); 13C-NMR: (125MHz, CDCl3) δ –5.1, –4.8, –4.68, –4.67, 12.0, 18.1, 18.2, 19.7, 22.1, 23.4, 
25.8, 25.9, 27.7, 28.8, 34.1, 40.5, 41.3, 44.8, 45.8, 46.1, 51.3, 56.3 (2C), 67.5, 72.1, 111.3, 118.1, 
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123.1, 135.2, 140.5, 148.3, 173.84; m/z calculated for C38H67NO4Si2Na 681 [M + ACN + H],+ found 
681; [𝛼]𝐷
25 = + 21.0 (c 1.0, CHCl3) 
 
 O-bis-silylated calcitroic acid: To a stirred solution of O-Bis-
silylated CTA methyl ester (101.0mg, 0.16mmol) in minimal 
MeOH (5mL) was added a solution of 10% NaOH (%w/v) in 
MeOH:H2O 9:1. The reaction stirred overnight at room 
temperature, then was neutralized with concentrated HCl to 
~pH 6. The neutralized reaction mixture was concentrated under reduced pressure to remove 
MeOH, then diluted with H2O (20mL). The mixture was extracted once with DCM, then acidified 
to pH 1 with concentrated HCl, and extracted with DCM again (3x20mL). Combined organic 
layers were dried over MgSO4 and concentrated to the O-bis-silylated CTA (70.5mg, 71%) as a 
white powder. No attempts were made to purify the product further; Rf 0.18 (EtOAc: Hex 1:7); 
1H-NMR (500MHz, CDCl3) δ 0.07-0.10 (m, 12H), 0.60 (s, 3H), 0.90 (s, 18H), 1.07 (d, J = 6.4 Hz, 3H), 
1.29-1.39 (m, 3H), 1.49-1.60 (m, 3H), 1.64-1.74 (m, 2H), 1.76-1.82 (m, 1H), 1.86-2.10 (m, 7H), 
2.24 (dd, J = 13.2, 7.5 Hz, 1H), 2.45-2.54 (m, 2H), 2.82-2.88 (m, 1H), 4.19-4.24 (m, 1H), 4.39 (dd, J 
= 6.6, 3.4 Hz, 1H), 4.89 (d, J = 2.5 Hz, 1H), 5.20 (d, J = 1.75 Hz, 1H), 6.04 (d, J = 11.2 Hz, 1H), 6.26 
(d, J = 11.2, 1H); 13C-NMR: (125MHz, CDCl3) δ –5.1, –4.8, –4.68, –4.67, 12.0, 18.15, 18.23, 19.7, 
22.1, 23.4, 25.8 (3C), 25.9 (3C), 27.7, 28.8, 34.0, 40.5, 41.1, 44.8, 45.8, 46.1, 56.2, 56.3, 67.5, 
72.1, 111.3, 118.1, 123.1, 135.3, 140.6, 148.3, 178.9; m/z calculated for C35H62O4Si2 603.4259 [M 
+ H]+, found 603.4147; [𝛼]𝐷
25 = + 26.0 (c 1.0, CHCl3) 
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 Calcitroic acid methyl ester: Tetrabutylammonium fluoride (1M in 
THF, 23mL, 23.3mmol) was added to a stirred solution of O-bis-
silylated CTA methyl ester (0.96g, 1.55mmol) in dry THF (20mL) 
at room temperature. The solution was stirred overnight, 
quenched with saturated NH4Cl solution (20mL) and extracted 
with EtOAc (3x50mL). The combined organic layers were washed with brine (50mL), dried over 
MgSO4, concentrated, and separated by column chromatography (EtOAc : Hex 7 : 3) to yield CTA 
methyl ester as a slightly yellow oil (0.53g, 88%); Rf 0.26 (EtOAc: Hex 7:3); 1H-NMR (500MHz, 
CDCl3) δ 0.57 (s, 3H), 0.98 (d, J = 6.4 Hz, 3H), 1.27-1.34 (m, 3H), 1.45-1.59 (m, 4H), 1.63-1.72 (m, 
2H), 1.81-1.95 (m, 4H), 1.96-2.03 (m, 4H), 2.30 (dd, J = 14.0, 8.0 Hz, 1H), 2.43 (dd, J = 14.5, 3.5 
Hz, 1H), 2.57 (dd, J = 13.7, 3.1 Hz, 1H), 2.82 (dd, J = 12.6, 4.3 Hz, 1H), 3.66 (s, 3H), 4.21 (m, 1H), 
4.42 (dd, J = 7.6, 4.5 Hz, 1H), 4.98 (s, 1H), 5.32 (s, 1H), 6.02 (d, J = 11.0 Hz, 1H), 6.35 (d, J = 11.0 
Hz, 1H); 13C-NMR: (125MHz, CDCl3) δ 12.0, 19.6, 22.2, 23.5, 27.6, 29.0, 34.1, 40.3, 41.3, 42.8, 
45.2, 45.9, 51.4, 56.3 (2C), 66.7, 70.6, 111.8, 117.3, 124.6, 133.4, 142.5, 147.7, 174.0; m/z 
calculated for C24H36O4 389.2686 [M + H]+, found 389.2618; [𝛼]𝐷
25 = —7.0 (c 1.0, CHCl3) 
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 Calcitroic acid: CTA methyl ester (0.52g, 1.33mmol) was dissolved 
in a solution of 10% NaOH in 9:1 MeOH:H2O (25mL) and stirred at 
room temperature for two hours. When all starting material had 
dropped to baseline by TLC, the reaction was neutralized with 
concentrated HCl to ~pH 7. Excess MeOH was evaporated under 
reduced pressure. The reaction was then diluted with H2O (25mL), acidified with concentrated 
HCl to pH 1, and extracted with EtOAc (3 x 30mL). The combined organic layers were washed 
with brine (25mL), dried over MgSO4, concentrated, and purified by column chromatography 
(EtOAc) to yield calcitroic acid (CTA) (0.40g, 80%) as a yellow solid; Rf 0.14 (EtOAc); 1H-NMR 
(500MHz, CDCl3) δ 0.60 (s, 3H), 1.06 (d, J = 6.5 Hz, 3H), 1.30-1.41 (m, 3H), 1.48-1.61 (m, 3H), 
1.67-1.76 (m, 3H), 1.86-1.98 (m, 4H), 1.98-2.12 (m, 4H), 2.34 (dd, J = 13.0, 6.5 Hz, 1H), 2.50 (dd, J 
= 15.0, 3.5 Hz, 1H), 2.62 (dd, J = 13.5, 3.2 Hz, 1H), 2.85 (dd, J = 13.6, 4.6 Hz, 1H), 4.26 (m, 1H), 
4.46 (dd, J = 4.2, 7.6, 1H), 5.02 (s, 1H), 5.35 (s, 1H), 6.04 (d, J = 11.2 Hz, 1H), 6.39 (d, J = 11.2 Hz, 
1H); 13C-NMR: (125MHz, CDCl3) δ 12.0, 19.7, 22.2, 23.5, 27.6, 29.0, 33.9, 40.3, 41.1, 42.8, 45.2, 
45.9, 56.2, 56.3, 66.9, 70.8, 111.9, 117.2, 124.9, 133.1, 142.7, 147.6, 178.4; m/z calculated for 
C23H34O4 373.2373 [M + H]—, found 373.2335; [𝛼]𝐷
25 = — 6.0 (c 1.0, CHCl3) 
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O-silylated calcioic acid methyl ester: A solution of n-
butyllithium (1.6 M in hexanes, 0.55mL, 0.565mmol) was added 
dropwise to a solution of calcioic acid A-ring phosphine oxide 
(500mg, 0.715mmol, dried over 3Å molecular sieves in 3 ml 
THF overnight) at -78°C using freshly dried 3Å molecular sieves. 
The solution turned deep red and was stirred for an hour at -78°C. Raising the solution out of the 
bath briefly deepened the red color and ensured that the deprotonation was complete. The 
solution was returned to the bath and C,D-ring ketone (147mg, 0.376mmol, dried over 3Å 
molecular sieves in 2 ml THF overnight) was added dropwise. The solution was stirred for 5 hours 
at -78°C and allowed to come to room temperature. The reaction mixture was then quenched 
with 10mL water, diluted with TBME, and extracted (TBME, 2x50mL). Combined organic layers 
were washed with brine, dried over MgSO4, and concentrated. The crude product was purified 
by column chromatography (EtoAc: Hex 5:95) to yield O-silylated calcioic acid methyl ester as a 
white crystalline solid (117mg, 41%); Rf 0.62 (EtOAc: Hex 1:9); 1H-NMR (500MHz, CDCl3) δ 0.06-
0.10 (m, 6H), 0.60 (s, 2H), 0.90 (s, 9H), 1.00 (d, J = 4.0 Hz, 2H), 1.26-1.37 (m, 3H), 1.48-1.62 (m, 
4H), 1.63-1.74 (m, 2H), 1.83-1.79 (m, 3H), 1.98-2.07 (m, 3H), 2.07-2.16 (m, 1H), 2.21-2.29 (m, 
1H), 2.35-2.41 (m, 1H), 2.41-2.50 (m, 2H), 2.81-2.88 (m, 1H), 3.68 (s, 3H), 3.79-3.87 (m, 1H), 4.79 
(s, 1H), 5.02 (s, 1H), 6.03 (d, J = 10.0 Hz, 1H), 6.17 (d, J = 10.0, 1H); 13C-NMR: (125MHz, CDCl3) δ -
4.6, -4.5, 12.1, 18.2, 19.7, 22.2, 23.4, 25.9 (4C), 27.7, 28.8, 32.8, 34.1, 36.4, 40.4, 41.4, 45.8, 46.9, 
51.4, 56.3 (2C), 70.6, 112.2, 118.0, 121.3, 136.6, 141.0, 145.4, 174.0; m/z calculated for 
C30H50O3Si 487.3602 [M + H]+, found 487.3542; [𝛼]𝐷
25 = + 61.0 (c 1.0, CHCl3) 
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 Calcioic acid methyl ester: To a stirred solution of O-silylated 
calcioic acid methyl ester (79mg, 0.16mmol) in dry THF (7mL), 
tetrabutylammonium fluoride (1M in THF, 1.6mL, 1.6mmol) was 
added. The reaction was stirred at room temperature overnight, 
then quenched with saturated NH4Cl solution (10mL). The mixture 
was extracted with EtOAc (3x20mL) and the combined organic layers were washed with brine 
(30mL), dried over MgSO4, concentrated, and purified by column chromatography (EtOAc: Hex 
3:7) to yield the calcioic acid methyl ester as a clear oil (55mg, 91%); Rf 0.16 (EtOAc: Hex 1:3); 1H-
NMR (500MHz, CDCl3) δ 0.59 (s, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.28-1.36 (m, 4H), 1.49-1.58 (m, 
3H), 1.64-1.71 (m, 3H), 1.84-1.98 (m, 4H), 1.98-2.04 (m, 3H), 2.15-2.22 (m, 1H), 2.26-2.32 (m, 
1H), 2.26-2.32 (m, 1H), 2.38-2.48 (m, 2H), 2.56-2.61 (m, 1H), 2.81-2.87 (m, 1H), 3.68 (s, 3H), 
3.92-3.98 (m, 1H), 4.82-4.83 (m, 1H), 5.05-5.07 (m, 1H), 6.04 (d, J = 11.2, 1H), 6.24 (d, J = 11.2, 
1H); 13C-NMR: (125MHz, CDCl3) δ 12.0, 19.7, 22.2, 23.5, 27.6, 28.9, 32.0, 34.1, 35.2, 40.4, 41.4, 
45.9, 46.0, 51.4, 56.2, 56.3, 69.2, 112.4, 117.8, 122.3, 135.4, 141.7, 145.1, 174.0; m/z calculated 
for C24H36O3 373.2737 [M + H]+, found 373.2664; [𝛼]𝐷
25 = + 18.0 (c 1.0, MeOH) 
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Calcioic acid: To a stirred solution of calcioic acid methyl ester 
(44mg, 0.12mmol) in ethanol (1.5mL) was added 1mL of 10% 
aqueous NaOH. After disappearance of starting material by TLC 
(around 1 hr), the reaction was neutralized with concentrated HCl 
to ~pH 7. Excess MeOH was evaporated off under reduced 
pressure. The reaction was then diluted with H2O (25mL), acidified with concentrated HCl to pH 
1, and extracted with EtOAc (3x5mL). The organic layers were washed with brine (5mL), dried 
over MgSO4, concentrated, and purified by column chromatography (EtOAc : Hex 4 : 1) to yield 
calcioic acid (25mg, 59%) as a white powder; Rf 0.53 (EtOAc); 1H-NMR (500MHz, CDCl3) δ 0.61 (s, 
3H), 1.06 (d, J = 6.5 Hz, 3H), 1.30-1.40 (m, 4H), 1.50-1.61 (m, 3H), 1.65-1.74 (m, 3H), 1.86-1.99 
(m, 4H), 1.99-2.10 (m, 3H), 2.17-2.23 (m, 1H), 2.30 (dd, J = 12.8, 5.5 Hz, 1H), 2.39-2.46 (m, 1H), 
2.51 (dd, J = 14.9, 3.0 Hz, 1H), 2.57-2.63 (m, 1H), 2.82-2.88 (m, 1H), 3.94-4.00 (m, 1H), 4.84 (s, 
1H), 5.07 (s, 1H), 6.06 (d, J = 10 Hz, 1H), 6.25 (d, J = 10 Hz, 1H); 13C-NMR: (125MHz, CDCl3) δ 
12.02, 19.66, 22.20, 23.46, 27.66, 28.93, 31.95, 33.93, 35.14, 40.37, 41.19, 45.87, 45.88, 56.16, 
56.27, 69.28, 112.49, 117.76, 122.32, 135.36, 141.71, 145.06, 178.96; m/z calculated for 
C23H34O3 359.2581 [M + H]+, found 359.2524; [𝛼]𝐷
25 = —17.0  (c 1.0, CHCl3) 
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1.7 Biological Characterization of Calcitroic Acid 
 
 
Background 
When DeLuca et al. isolated and characterized CTA, they also determined the affinity of 
CTA for VDR and the vitamin D binding protein, which was 6.8μM and 10μM, respectively.  
Applying mouse models in 1981, they observed some calcification of the epiphyseal plate of rats 
maintained on a low phosphorus diet after a 7 day, 50ng/animal subcutaneous CTA treatment, 
albeit 3 times less than what occurred with 5ng/animal treatment with calcitriol.92 Because of 
the relative low affinity for CTA towards VDR, further investigations were not conducted.  
In vitro investigations conducted a decade later using a luciferase assay under control of a 
mouse osteopontin vitamin D response element (VDRE) in melanoma epithelial cells found that 
at 20nM, CTA gene transcription was significantly upregulated in comparison to other 25-hydoxy 
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vitamin D3 metabolites.100 Similar results were observed with a luciferase transcription assay 
using a CYP24A1 promoter VDRE.101 However, at 20nM CTA, no induction of the CYP24A1 gene 
in HaCaT cells (immortalized keratinocyte) was observed when incubated for 4 hours or 24 
hours.  
Recently, the Arnold lab showed that while CTA was inactive in promoting the 
recruitment of SRC2-3 to VDR, it was able to inhibit this interaction with an IC50 of 6.12 ± 2.1 μM 
in the presence of calcitriol. Using a two-hybrid assay to investigate the interaction between VDR 
and coregulator SRC-1, we have shown that CTA 
promoted this interaction with an EC50 of 0.85 ± 0.33 
μM but only 55% efficacy was achieved in 
comparison to 20nM calcitriol. Thus, from these 
initial results we can conclude that CTA behaves like 
a partial VDR agonist. Further transcription assays 
using DU145 prostate cancer cells demonstrated that 
CTA induced VDR target gene CYP24A1 9-fold at 
7.5μM (see Figure 16). Also in this case, the 
induction was significantly lower than calcitriol at 
20nM.  
It is known that VDR regulates expression of CYP24A1102 in addition to CYP27B1103 in 
order to regulate the formation and catabolism of calcitriol. It also regulates CYP3A4,104 
CYP19A1,105 and CYP1A1106 as a xenobiotic sensor similar to the pregnane X receptor (PXR) and 
Figure 16: CYP24A1 upregulation by synthetic phase 2 
metabolites of lithocholic acid, LCA, and CTA (7.5μM) in 
DU145 prostate cancer cells, with 1,25(OH)2D3  (20nM) as 
a positive control and DMSO at a negative control. 
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constitutive androstane receptor (CAR).107 Thus, vitamin D metabolites including CTA might play 
a role in detoxification by interacting with VDR and taking part in the regulation of several 
metabolic enzymes.  
The synthesis of CTA enabled us to generate large quantities of CTA and to compare its 
properties to that of previously purchased CTA.  
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Interaction with VDR using fluorescence polarization 
Fluorescence polarization (FP) is a fluorescence-based detection method that enables us 
to differentiate between the molecular sizes of fluorescent complexes using monochromatic 
polarized light. Small fluorescent compounds depolarize monochromatic emitted light due to 
their fast rotation in solution; however, fluorescent compound-protein complexes have a low 
tendency to depolarize light due to their slow tumbling in solution. For this competition assay we 
are using a fluorescent peptide that is derived from VDR coactivator SRC2-3 and recombinant 
expressed VDR-LBD and synthetic agonist LG190178. For this experiment, protein, peptide, and 
LG190178 are incubated in the presence of different concentrations of CTA and CTA methyl ester 
(Figure 17). 
 
  
Figure 17: Modulation of binding of SRC2-3 to VDR-LBD in presence of LG190178 as a function of displacement by CTA (A) 
and CTA methyl ester (B). 
Calcitroic Acid  Calcitroic Acid Methyl Ester 
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Interaction with other nuclear receptors using a fluorescence polarization assay  
After confirming that CTA binds to VDR, it is important to verify that this interaction is 
specific to VDR among other nuclear receptors (NR). To this end, FP data was collected for the 
binding of CTA to several other nuclear receptors including the androgen receptor, estrogen 
receptor β, retinoid X receptor α, thyroid hormone receptor α, thyroid hormone receptor β, and 
peroxisome proliferator-activated receptor γ (Figure 18).  
For all assays, recombinantly expressed NR-LBDs were incubated with the corresponding 
labeled coactivator peptide in the presence of different concentrations of CTA. All six nuclear 
receptor assays did not show any change of FP. Thus, we can conclude that among the nuclear 
receptors tested, CTA binding to VDR is specific.   
Figure 18: Other nuclear receptors and their fluorescently labeled peptide sequences did not depolarize light in the presence of 
CTA, providing evidence that CTA’s binding to VDR is specific.  
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Interaction with VDR using x-ray crystallography 
CTA was sent to collaborator Natacha Rochel, who generated 
crystals of CTA bound to both a human and zebrafish recombinant 
VDR-LBD. The protein was concentrated using Amicon ulta-30 
(Millipore) to 3-7mg/mL and incubated with 2x excess of CTA and 3x 
excess of coactivator peptide. Crystallization experiments occurred at 
48°C. Crystals of hVDR complexed with CTA were obtained from a 
solution containing 0.2M 
ammonium sulfate, 2.7M sodium formate, and 0.1M 
PIPES (pH 7.0) (Figure 22A). Crystals of zVDR 
complexed to CTA were obtained from a solution 
containing 1.8M LiSO4 and 0.1M Mes (pH 6.0) (Figure 
22B). Protein crystals were mounted in a fiber loop Figure 19: Stick-figure overlays of calcitriol (cyan) 
and CTA (yellow) within the binding pocket of VDR. 
Figure 20: Protein-ligand interactions between CTA and 
VDR. Green arrows indicate side-chain 
donation/acceptance.  
Figure 21: CTA in the binding pocket of zVDR LBD. The two OH 
residues on the A-ring (lower left, red) are anchored by 
donor/acceptor interactions with Tyr, Ser, and Arg residues, 
while the acid function (upper right, red) interacts with histidine. 
Figure 22: Protein crystals of 
(A) human LBD-VDR and (B) 
zebrafish LBD-VDR 
A 
B 
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and flash-cooled under nitrogen flux after cryo-protection with 20% glycerol. X-ray data has been 
collected from the crystals followed by homology modeling. Overlaying of CTA with calcitriol 
(Figure 19) visualizes the same binding mode of CTA and calcitriol. CTA forms several 
donor/acceptor interactions with VDR. Serine 306 and tyrosine 175 interact with the 3-OH of 
CTA, serine 265 and arginine 302 interact with 1-OH of CTA (Figure 23B), and histidine 423 
interacts with the acid functionality of CTA (Figure 23A). The hydrophobic central ring structure 
of CTA aligns well with the hydrophobic side chains present in the center of the VDR binding 
pocket (Figure 21).    
 
 
 
 
 
 
Figure 23: Detailed view of donor/acceptor interactions. (A) The acid functionality on CTA’s side chain interacts through 
solvent contact with His 423. (B) On the other end of the molecule and binding pocket, the two hydroxyl groups make both 
donor and acceptor contacts with Ser 306, Tyr 175, Ser 265, and Arg 302. 
A 
B 
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Interaction with other nuclear receptors using a FRET-based assay 
Fluorescence resonance energy transfer, or FRET, is a phenomenon where two light-
sensitive chromophores situated within a certain distance of each other can transfer energy from 
an exited state in the donor chromophore to the acceptor chromophore. Because the 
wavelength used to excite the donor chromophore is different from the emission wavelength of 
the acceptor chromophore, there is very low background radiation. Because FRET emission only 
occurs when donor and acceptor chromophores are very close together and is proportional to 
the sixth power of the distance between them, FRET is extremely sensitive to changes in distance 
between the two. This makes the use of FRET technology for measuring binding very useful. The 
recently developed BODIPY FL vindoline108 is a fluorescent FRET probe specific to PXR. A terbium 
labeled anti-GST antibody is used to enable time resolved FRET by taking advantage of the 
persistent fluorescence of lanthanides. Both PXR-LBD and CAR-LBD were generated with a GST 
tag. The displacement of the probe by compounds that bind to the LBD of PXR reduce the FRET 
signal, allowing for accurate assessment of PXR‒ligand inhibition. A similar principle was used for 
A B 
Figure 24: (A) The PXR-BODIPY FL vindoline interaction was not inhibited in the presence of CTA. (B) The CAR-PGC1α 
interaction was not inhibited in the presence of CTA. 
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the FRET assay for the constitutive androstane receptor (CAR). However, in this case CAR-LBD was 
incubated with a labeled coactivator PGC1α,109 which will bind CAR in the presence of an agonist 
such as CITCO. When PXR-BODIPY FL vindoline was treated with CTA (Figure 24A) or when CAR-
PGC1α was treated with CTA (Figure 24B), no inhibition of the FRET interaction took place, 
providing further evidence that CTA does not participate in binding with PXR and CAR.  
 
 
 
 
 
 
 
 
 
 
 
  
b) TR-FRET with 
fluorescein-
labeled 
PGC1peptide 
and hCAR labeled 
with Tb-anti-GST 
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Interaction with VDR using a transcription assay  
With the confirmation from these protein assays that CTA did indeed bind specifically to 
VDR, we began cell-based assays to determine more about CTA’s cell permeability and biological 
relevance. A transcription assay uses plasmids that are transfected into cells (HEK293T) to enable 
the generation of promoter-specific luciferase. For our assay, a cytomegalovirus promoter 
causes overexpression of VDR, and the reporter plasmid’s luciferase gene is under control of a 
CYP24A1 promoter. Thus, in the presence of an agonist, activated overexpressed VDR recognizes 
the CYP24A1 VDRE and recruits RNA polymerase to transcribe the luciferase reporter gene. The 
bioluminescence of the generated enzyme in the presence of substrate (luciferin) is directly 
proportional to the amount of VDR-mediated transcription.  
Dr. Teske showed for the first time that CTA behaves like a partial agonist in cells (Figure 
25). In the presence of 10nM calcitriol, increasing the concentration of CTA will reduce the level 
of transcription as low as 20% at concentrations higher than 100μM. The IC50 for this inhibition is 
3.2 ± 2.4 μM. In the absence of calcitriol, CTA is able to activate VDR-mediated transcription to 
Figure 25: Combined dose response curves showing partial agonistic 
activity (teal) and competitive inhibition in the presence of calcitriol 
(pink) of CTA with VDR. 
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up to 20% of calcitriol transcriptional activity at 10nM with an EC50 of 2.5 ± 1.0 μM. Thus, 
interestingly, CTA inhibits the binding of calcitriol, but it also acts as a partial agonist at nearly the 
same concentration.  
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Interaction with other nuclear receptors using transcription assays 
The transcriptional activity of other nuclear receptors in the presence of CTA was 
assessed by Prof. Merk’s laboratory (Goethe University Frankfurt). In their assays, plasmids 
bearing NR-LBDs fused to a GAL4 DNA binding domain and a luciferase reporter with a UAS 
promoter site are used. Cell were transfected overnight and treated with different concentration 
of CTA (Figure 26). 
 In all cases tested, positive control compounds upregulated transcription of each nuclear 
receptor. However, CTA at different concentrations did not influence transcription. This result 
provides further evidence that the binding of CTA is specific to VDR.  
  
A B 
C D 
Figure 26: Transcriptional activity was absent in assays of other nuclear receptors treated with CTA. 
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Effect of CTA on macrophages 
VDR is expressed in leukocytes, and calcitriol has been shown to modulate the immune 
system and suppress immune responses.110 Macrophages, a type of phagocytic white blood cell 
which engulfs and neutralizes foreign substances, are activated by infection and can maintain 
inflammation.111 When stimulated to express an immune response, the activated M1 “killer” 
macrophages release inflammatory cytokines like IL-1, IL-12, and IL-23 and induce iNOS, the nitric 
oxide synthase involved in immune response. These transcriptional inflammatory products can 
be quantified by qRT-PCR (Figure 27B). Nitric oxide (NO) release can be measured by the 
formation  of a brightly colored azo compound using a Griess assay (Figure 27A).112  
Figure 27: (A) Nitric oxide suppression as measured by Griess assay following stimulation with 150units/mL IFNγ and 
50ng/mL LPS in RAW264.7 murine macrophages. 1,25(OH)2D3  and CTA exhibited a decrease in NO, along with the positive 
control dexamethasone. (B) Downregulation of mRNA of inflammatory species in the presence of CTA and calcitriol, along 
with positive control dexamethasone. 
mRNA Upregulation  A B 
Nitric Oxide Release 
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To investigate whether CTA in addition to calcitriol can reduce inflammation, rat 
macrophages (RAW264.7, ATCC TIB-71) were stimulated with 150units/mL IFNγ and 50ng/mL LPS 
and dosed with calcitriol (20nM) and CTA (20μM) using DMSO (vehicle) and dexamethasone as 
negative and positive controls, respectively. The supernatant media from these cells was used for 
the Griess assay after 18 hours at 37°C, while the cells were harvested and their mRNA isolated. 
Figure 27a shows a strong elevation of NO when cells were treated with IFNg/LPS and vehicle 
DMSO.  
Interestingly, calcitriol, CTA and dexamethasone reduced NO formation, although at 
different concentrations. Similarly, mRNA of iNOS and IL-1b were downregulated by calcitriol, 
CTA, and dexamethasone. This is consistent with our hypothesis that CTA interacts with VDR and 
can regulate transcription.  
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Effect of CTA on intestinal epithelial cells 
Starting with colon cancer (Caco2) cells as a 
preliminary model of the intestinal barrier, cells were 
treated with CTA along with LCA (a known weak ligand of 
VDR that can induce gene expression in the ileum113) with 
DMSO and calcitriol as negative and positive controls, 
respectively. We monitored the upregulation of CYP3A4 
mRNA, along with that of several other CYP genes known 
to be mediated by VDR (CYP2B6, CYP2C9).114 We observed specific upregulation of CYP3A4 
mRNA by CTA but not that of other VDR-mediated enzymes CYP2B6 and CYP2C9 (Figure 28).  
The much slower-growing normal human 
intestinal epithelial cell line (HIEC-6) derived from 
crypt cells was then purchased and cultured. In the 
process of seeking out a better primer for CYP3A4, 
we made an interesting discovery. When running an 
agarose gel to ensure the selectivity of our CYP24A1 
primers, calcitriol upregulated both the 317 kDa and 
the 119 kDa splice variants of CYP24A1, which was 
expected. However, CTA preferentially upregulated 
the 317 kDa variant, with no 119 kDa splice variant seen (Figure 29). This was repeated several 
Figure 28: CYP3A4 upregulation by CTA (6μM) in 
Caco2 cells. DMSO is a negative control. No 
upregulation of other CYP mRNA was seen under 
these conditions. 
Figure 29: Gel of CYP3A4 primer, which is 
differentially upregulated by CTA and calcitriol. 
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times with the same result. Investigating this surprising and specific difference may be a target of 
future studies.  
mRNA quantification was achieved by qRT-PCR (Figure 30). We observed that calcitriol at 
20nM highly upregulated both CYP24A1 and CYP3A4 in HIEC6 cells. In comparison to 10μM LCA, 
10μM CTA resulted in a more pronounced transcription of both CYP24A1 and CYP3A4, whereas 
LCA induced no significant transcription. This evidence furthers the hypothesis that CTA may play 
an integral part in detoxification by elevating CYP3A4 levels, an enzyme which is known to 
metabolize LCA in the intestines.115 
 
  
Figure 30: Upregulation by CTA and lithocholic acid (both 10μM) in HIEC6 human normal intestinal epithelial cells, with 
1,25(OH)2D3 (20nM) as a positive control and DMSO at a negative control, against CYP3A4 (A) and CYP24A1 (B). 
 
A B 
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Stability of CTA in the presence of P450 enzymes 
It has been established that CYP3A4 plays a role in the hydroxylation of calcitriol as part of 
its metabolic breakdown in intestines and liver.116 We investigated the stability of both CTA and 
calcitriol in human liver microsomes (HLM) in order to determine the stability of CTA in the 
presence of P450 enzymes including CYP3A4. Therefore, HLM were incubated in the presence of 
CTA and aliquots were taken at specific time intervals. The concentrations of CTA were 
determined by LCMS-MS and presented as their natural logarithm vs. time (Figure 31).   
While we saw the expected breakdown of calcitriol under these conditions, we did not 
observe metabolism of CTA during a period of 2 hours. Calcitriol exhibited a half-life of around 
two hours. This experiment confirms that CTA is not further changed through phase I 
metabolism. In order to investigate if CTA inhibits P450 enzymes, calcitriol was incubated in the 
presence of CTA (Figure 31C). Because the half-life of calcitriol is not changing whether CTA is 
present of not, we can conclude that CTA is not inhibiting P450 enzyme activity.   
  
A B 
Figure 31: Microsomal digestion of CTA (A), calcitriol (B), and both CTA and calcitriol (C). 
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Discussion 
The biological data collected on CTA indicates that CTA is not the inactive metabolic 
byproduct it had long been assumed to be. Binding data show that CTA binds specifically to VDR 
among other nuclear receptors.  X-ray crystallography confirmed this interaction and shows that 
CTA adopts the same binding mode as calcitriol.  
Cell-based assays demonstrate that CTA is cell membrane-permeable and inhibits the 
interaction between VDR and calcitriol. However, the inhibition is partial (80%), because CTA is 
also able to activate VDR-mediated transcription with an efficacy of 20%. Because both equilibria 
occur at the same concentration, CTA can be described a partial agonist/antagonist.     
When metabolism to CTA occurs in the kidney it can lead to urinary excretion; however, 
phase II metabolism conjugation in the liver could lead to intestinal secretion of conjugated 
vitamin D metabolites as bile. In the intestines, bacteria and intestinal cells can reverse this 
process, which would liberate vitamin D metabolites to be reabsorbed and contribute to 
enterohepatic circulation. Evidence already suggests that bile carries large quantities of vitamin 
D metabolites, which were isolated and characterized during the last 40 years.69 Our work is 
focused on the physiological activity of CTA in the intestine.  
One important cell type mediating the immune response in the intestine are 
macrophages. It has been reported that macrophages mediate diseases such as inflammatory 
bowel disease.117 We were able to show for rat macrophages that CTA in addition to calcitriol can 
significantly decrease inflammation based on the reduction of two inflammation markers, IL-1b 
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and iNOS, in the presence of IFNγ/LPS. Thus, we believe that CTA is acting as a natural anti-
inflammatory molecule.   
Another important intestinal cell type are epithelial cells that are part of the 
gastrointestinal wall. These cells are known to express P450 enzymes to combat xenobiotic 
toxicity.118 We have shown that CTA and calcitriol were able to upregulate the transcription of 
these enzymes in vitro. Furthermore, we observed that the regulation of CYP24A1 differs 
between CTA and calcitriol. Further investigations are necessary to investigate this phenomenon.  
In conclusion, we are presenting compelling evidence for the link between the 
detoxification of the gut and VDR’s CTA-mediated activity. We believe that the water-soluble 
metabolites of vitamin D that are secreted into the intestinal tract protect the colon from 
inflammation-inducing accumulation of xenobiotics such as lithocholic acid by upregulation of 
CYP3A4.85 Vitamin D has been shown to provide a noticeable amount of relief from symptoms in 
IBD as well.119 The mechanism by which this relief takes place remains unknown, and these 
results indicate that it could be mediated in part by CTA.  
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Experimental Procedures: 
Fluorescence Polarization Binding Assay Protocol 
The FP assay buffer was prepared by adding 25mM PIPES (piperazine-N,N’-bis(ethanesulfonic 
acid, Sigma-Aldrich), 50mM NaCl (Fisher), and 0.01% NP-40 detergent to 18.2MΩ water. The 
buffer was filtered and adjusted to pH 6.75. To this was added 7.5nM of the coactivator peptide 
SRC2-3 (CKKKENALLRYLLDKDDTKD) which had been labeled with cysteine-reactive AlexaFluor647. 
To this solution was added 250nM of VDR-LBD, which had been expressed and purified as 
reported previously.120 The VDR agonist LG190178, which had been synthesized previously 
according to a published protocol,121-122 was added at a concentration of 600nM. A 10mM stock 
of CTA in DMSO was serially diluted (1:2) in a 384-well plate (Corning, CLS3702). To a 384-well 
black polystyrene microplate (Corning, CLS3658), 20μL of the prepared VDR-LBD assay solution 
was dispensed to test against the CTA serial dilution. Using the Tecan Freedom EVO liquid handler 
system and a 100nL pin tool (V&P Scientific), a total of 200nL of each CTA concentration was 
transferred in quadruplicate to the 20μL assay solution for a final maximum concentration of 
100μM CTA. Following incubation for 1 hour, fluorescence polarization was detected at an 
excitation/emission wavelength of 635/685 nm using the Tecan Infinite M1000 plate reader. The 
result showed CTA binding at an IC50 of 8.5μM. To verify specificity, CTA was investigated with 
other nuclear receptors and their respective agonists and coactivators (thyroid receptor α LBD 
(2μM)/Texas Red-labeled SRC2-2 (7nM)/triiodothyronine (1μM); thyroid receptor β LBD 
(0.8μM)/Texas Red-labeled SRC2-2 (7nM)/triiodothyronine (1μM); peroxisome proliferator-
activated receptor γ (5μM)/Texas Red-labeled DRIP2 (7nM)/rosiglitazone (5μM); androgen 
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receptor LBD (5μM)/Alexa Fluor 647-labeled SRC2-3 (7nM)/dihydrotestosterone (10nM); 
estrogen receptor β LBD (5μM)/Texas Red-labeled SRC2-2 (7nM)/estradiol (20nM)). 
 
Transcription Assay Protocol 
Human embryonic kidney (HEK293, ATCC CRL-3249) T cells were cultured in DMEM/High 
Glucose (Hyclone, #SH3024301) with non-essential amino acids (Hyclone, #SH30238.01), 10 mM 
HEPES (Hyclone, #SH302237.01), 5 x 106  units of penicillin and streptomycin (Hyclone, 
#SV30010), and 10% of FBS (Gibco, #10082147). Transfection was carried out with 70-80% 
confluent cells. For VDR transfection, 2 mL of untreated DMEM/High Glucose media containing 
0.7 μg of VDR-CMV plasmid, 16 μg of a CYP24A1-luciferase reporter gene, LipofectamineTM LTX 
(75 μl, Life Technologies #15338020), and PLUSTM reagent (25 μl) was added to the flask. After 
16 hours of incubation at 37oC with 5% CO2, the cells were harvested with 3mL of 0.05% Trypsin 
(Hyclone, #SH3023601), added to 10mL of the assay buffer (DMEM/High Modified buffer 
without phenol red, Hyclone #SH30284.01) and spun down for 2 minutes at 1000 rpm. The 
media was removed and cells were resuspended in the DMEM assay media. Prior to adding cells 
to sterile white, optical bottom 384-well plates, plates were treated with 20 μL per well of a 
0.25% matrigel solution. To each well, 20μL of cells were added to yield a final concentration of 
15,000 cells per well. The plates were then spun down for 2 minutes at 1000 rpm. After four 
hours, plated cells were treated with 100 nL of compounds and controls which were added using 
the EVO liquid handling system with a 100nL pin tool (V&P Scientific). Controls used with VDR 
were 1,25(OH)2D3 (10 nM in DMSO, Endotherm) and DMSO. After 16 hours of incubation at 37oC 
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with 5% CO2, 20μL of Bright-Glo™ Luciferase Assay Kit (transcription assay, Promega, Madison, 
WI) were added and luminescence was read on the Tecan Infinite M1000 reader.   
 
Transcription Assay (provided by Prof. Daniel Merk) 
HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM), high glucose with 
10% fetal calf serum (FCS), sodium pyruvate (1mM), penicillin (100U/mL), and streptomycin 
(100μg/mL) at 37°C and 5% CO2. Twenty-four hours before transfection, HEK293T cells were 
seeded in 96-well plates (3 × 104 cells/well). Before transfection, medium was changed to 
OptiMEM without supplements. Transient transfection was carried out using Lipofectamine LTX 
reagent (Invitrogen) according to the manufacturer’s protocol with pFR-Luc (Stratagene), pRL-
SV40 (Promega), and the corresponding Gal4-fusion nuclear receptor plasmid. Five hours after 
transfection, medium was changed to OptiMEM supplemented with penicillin (100 U/mL), 
streptomycin (100 μg/mL), and additionally containing 0.1% dimethyl sulfoxide (DMSO) and the 
respective test compound or 0.1% DMSO alone as untreated control. Each concentration was 
tested in duplicates and each experiment was repeated independently at least three times. After 
overnight (14−16 h) incubation with the test compounds, the cells were assayed for luciferase 
activity using the Dual-Glo Luciferase Assay System (Promega) according to the manufacturer’s 
protocol. Luminescence was measured with an Infinite M200 luminometer (Tecan Deutschland 
GmbH). Normalization of transfection efficiency and cell growth was done by division of firefly 
luciferase data by Renilla luciferase data and multiplying the value by 1000 resulting in relative 
light units (RLU). Fold activation was obtained by dividing the mean RLU of a test compound at a 
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respective concentration by the mean RLU of the untreated control. Relative activation was 
obtained by dividing the fold activation of a test compound at a respective concentration by the 
fold activation of a respective reference agonist:  RXRα: bexarotene (EC50: 33nM) LXRα/β: 
T09021317 (EC50 ∼ 50nM); FXR: GW4064 (EC50 = 70nM). All hybrid assays were validated with 
the above-mentioned reference agonists which yielded EC50 values in agreement with the 
literature. 
 
Griess Assay Immune Modulation Protocol 
The murine macrophage cancer cell line RAW264.7 was cultured in DMEM (ATCC 30-2002) with 
10% FBS. To initiate an immune response, cells were suspended at a cell density of 1x106 
cells/mL and a control sample (3mL) was dispensed into a 6-well clear-bottomed sterile plate 
with a lid (Corning 3516). The remaining suspended cells were then activated with interferon 
gamma (IFNγ, 150units/mL) and lipopolysaccharide (LPS, 50ng/mL). Activated cells were 
dispensed into the 6-well plate (3mL/well). Cells were then dosed with compounds of interest to 
the following final concentrations: calcitriol (20nM), CTA (5μM, 20μM), with dexamethasone as a 
positive control (10μM), and DMSO as a negative control. The plated cells were then allowed to 
incubate for 18 hours. Following incubation, aliquots of the supernatant (80μL) from each 6-well 
sample were taken in replicates of 8 and transferred to a 384-well clear-bottomed plate with a lid 
(CLS3700). To each aliquot was added 10μL of sulfanilamide solution (Promega Griess Reagent 
System, TB229). The covered plate was shaken briefly and incubated in the dark for 10 minutes. 
Following this, 10μL of NED solution (Promega Griess Reagent System, TB229) was added to each 
 
 
81 
 
 
aliquot. The plate was again shaken briefly and incubated in the dark for 10 minutes. The 
absorbance of the plate was then read on the Tecan Infinite M1000 plate reader (530nm).  
 
Quantitative Real Time Polymerase Chain Reaction Protocol 
The human colon cancer cell line Caco2 (ATCC HTB-37) or the human normal intestinal epithelial 
cell line HIEC-6 (ATCC CRL-3266) were purchased and cultured according to ATCC’s listed method. 
The cells were harvested with 0.25% Trypsin and then were plated (3mL) in a 6-well clear-
bottomed sterile plate with lid (Corning 3516) at a concentration of 1x106 cells/mL. The plate was 
incubated overnight at 37°C for the cells to settle and adhere to the plate. Cells were then dosed 
with compounds of interest to the following final concentrations: calcitriol (20nM), CTA (20μM), 
lithocholic acid (20μM), and DMSO as a negative control. The plate was incubated for 24 hours at 
37°C. The cell media was then removed, the cells rinsed briefly with PBS, and then harvested 
with 300μL of 0.25% Trypsin. The Trypsin was then diluted when cells were free by addition of 
700μL of normal media. The suspended cells were then transferred to Eppendorf 1.5mL tubes. 
The cells were spun down at 1800rpm for 5 minutes to form a pellet. The media was removed 
and the cells disrupted by adding 350μL of 1% β-mercaptoethanol in Buffer RLT (from Qiagen 
RNeasy Mini Kit 74104) to each and vortexing. The lysate was pipetted directly onto QIAshredder 
spin columns (Qiagen 79654) in a 2mL collection tube and centrifuged for 2 minutes at 1800rpm. 
To the homogenized lysate 350μL of 70% ethanol was added. The 700μL of solution was 
transferred to the RNeasy spin column and spun down at 1800rpm for 15 seconds. Flow-throughs 
were discarded and the column was washed sequentially with 700μL Buffer RW1, 500μL Buffer 
 
 
82 
 
 
RPE x2, and then the RNA eluted into a 1.5mL collection tube with 50μL of The RNA Storage 
Solution (Ambion, AM7001). The amount of RNA collected and its purity was measured by 
measuring UV signal at 260nm with the Tecan Infinite M1000. Samples of RNA were then taken 
and added to a solution containing forward and reverse primers for the sequences of interest 
along with the calculated amounts of quantifastRT, SYBR Green solution, and RNase-free water. 
Primers used for various experiments included the GAPDH housekeeping gene (forward: 5’-
ACCACAGTCCATGCCATCAC-3’ reverse: 5’-TCCACCACCCTGTTGCTGTA-3’), CYP3A4_1 (forward: 5’-
CCTACATATACACACCCTTTGGAAG-3’ reverse: 5’-GGTTGAAGAAGTCCTCCTAAGCT-3’)(Blast see 
below), CYP3A4_2: (forward: 5’-CACAAACCGGAGGCCTTTTG-3’ reverse: 5’-
ATCCATGCTGTAGGCCCCAA-3’) (Blast see below) CYP2B6 (forward: 5’-
GGCCATACGGGAGGCCCTTG-3’ reverse: 5’-AGGGCCCCTTGGATTTCC-3’), and CYP2C9 (forward: 5’-
TCCTATCATTGATTACTTCCCG-3’ reverse: 5’-AACTGCAGTGTTTTCCAAGC-3’). Replicates were 
pipetted into a 96-well PCR plate (Eppendorf 951022003). The program used on the thermal 
cycling machine (Eppendorf AG22331 Hamburg Mastercycler) was 5 minutes at 95°C (initial 
activation step), and then cycling through 10 seconds at 95° C (denaturation step) and 30 
seconds at 60°C (annealing step) for 50 cycles.  
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Microsomal Stability Assay Protocol 
8µL of 1mM test compound (at a final concentration of 20µM) in DMSO was pre-incubated at 
37°C for five minutes on a digital heating shaking dry bath (Fischer scientific, Pittsburgh, PA) in a 
mixture containing 274µL of water, 80µL of phosphate buffer (0.5M, pH 7.4), 20µL of NADPH 
Regenerating System Solution A (BD Bioscience, San Jose, CA) and 4µL of NADPH Regenerating 
System Solution B (BD Bioscience, San Jose, CA) in a total volume of 391.2µL. Following pre-
incubation, the reaction was initiated by addition of 8.8µL of either human liver microsomes (BD 
Gentest, San Jose, CA) or mouse liver microsomes (Life technologies, Rockford, IL), at a protein 
concentration of 0.5mg/mL. Aliquots of 50µL were taken at time intervals of 0 (no microsomes), 
10, 20, 40, 60, 90 and 120 minutes (calcitriol) or 0 (no microsomes), 20, 40, 60, 80, 100, and 120 
minutes (CTA). Each aliquot was added to 100µL of cold methanol solution containing 450nM of 
4,5-diphenylimidazole (4,5–DPI) (for a final concentration of 300-nM) as internal standard in a 96 
well plate. The quenched samples were transferred to a filter plate and vacuum filtrated. The 
filtrate was diluted 10-fold and analyzed subsequently by LC-MS/MS with the Shimadzu LCMS 
8040 instrument. CTA and calcitriol were monitored under positive mode by Shimadzu 8040 
triple quadrupole mass analyzer (Shimadzu, Kyoto, Japan) with electrospray ionization (ESI). The 
following transitions are monitored in multiple reaction monitoring (MRM) mode. Transitions for 
calcitriol were m/z 434.30 > 399.35, 434.30 > 381.35, 434.30 > 363.35, and 434.30 > 227.15. 
Transitions for CTA were m/z 375.35 > m/z 357.25, m/z 375.35 > m/z 339.25, and m/z 375.35> 
m/z 121.15. Transition pairs for verapamil are m/z 455.60 > m/z 303.20, m/z 455.60 > m/z 
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165.20, and m/z 455.60 > m/z 150.00. Collision energy is optimized for each transition to obtain 
optimal sensitivity. The mass spectrometer was operated with the heat block temperature of 
400°C, drying gas flow of 15L/min, desolvation line temperature of 250°C, nebulizing gas flow of 
1.5L/min, and both needle and interface voltages of 4.5kV. 
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1.8 The Phase II Metabolism of Calcitroic Acid 
 
 
Two principal phases of metabolism exist in living organisms: Phase I (oxidation, 
reduction and hydrolysis) and Phase II (conjugation). Phase I metabolism has been introduced in 
Chapter 1.3; it takes place predominately in the kidneys and liver and transforms vitamin D into 
its metabolites, including both calcitriol and CTA.123 More broadly speaking, Phase I metabolism 
uses various enzymes to convert xenobiotics in the bloodstream into corresponding metabolites 
with increased solubility by unmasking polar functional groups or by adding new ones to the 
existing molecule.124 Typically, the xenobiotic metabolite is less toxic and more easily excreted 
through urine and bile. For pharmaceuticals, metabolism typically reduces their pharmacologic 
activity.125 However, in some cases metabolism increases the physiological activity of certain 
compounds.126 This has long been known to be the case for vitamin D, which does not interact 
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with the vitamin D receptor; however, upon metabolism, calcitriol and several other metabolites 
do.127 
Phase II metabolism refers to the conjugation of compounds to polar molecules which is 
meditated by enzymes in living organisms. Sometimes, the conjugation occurs at positions that 
were generated by phase I metabolism through oxidation or unmasking, such as a hydroxyl 
group.128 The addition of water-soluble functional groups increases the overall solubility of the 
xenobiotic, and as a result it typically reduces toxicity and negates pharmacological activity.129 
The enzymes involved in these transformations are typically associated with activated 
coenzymes and transfer the polar compound from the cofactor to the xenobiotic species, 
although in some cases the opposite occurs and the coenzyme associates with the xenobiotic, 
transferring it onto the polar group in the presence of the transferase enzyme.128 Phase II 
metabolism occurs in the canonical metabolic sites, the liver and kidneys, but also can occur in 
other organs, such as the intestines, lungs, and skin.130  
The phase II metabolites of vitamin D metabolic products have yet to be investigated. It is 
surprising that despite the wealth of knowledge about vitamin D2 and D3 and the recognition 
that their VDR activity occurs only after metabolism,131 only the phase I metabolites have been 
the focus of research. To address this lack of knowledge, our group is investigating phase II 
conjugates of vitamin D metabolites. Our first focus is on the final metabolite CTA because of its 
stability, unique carboxylic acid functionality,7 and relative abundance in the body.5 While 
conjugation in the kidney often leads to urinary excretion, the liver’s conjugation processes can 
excrete vitamin D metabolites into the intestines as bile by way of the bile duct.132 We already 
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know that the bile is likely the location of the highest concentration of CTA, which nearly 40 
years ago was isolated as its corresponding methyl ester.8 As such, we expect that conjugates of 
vitamin D metabolites will likely be found there as well. It is known that bacteria in the gut can 
reverse conjugations,133 leading to a likely scenario where the intestines are exposed to an 
elevated concentration of unconjugated vitamin D metabolites, which in turn can be reabsorbed 
and induce a physiological effect. We have shown that this phenomenon could have important 
biological ramifications for CTA, which mediates multiple physiological effects, e.g. upregulation 
of CYP3A4 in gut epithelia cells.4 This pharmacological effect is particularly important with 
reference to lithocholic acid, the toxic bile acid which is known to be metabolized by P450 
enzyme CYP3A4.134 The CYP3A4 gene is regulated transcriptionally by the vitamin D receptor.135 
Interestingly, lithocholic acid interacts weakly with VDR and influences its own catabolism 
through its induction of CYP3A4.136 Our hypothesis is thus that CTA, as a ligand interacting with 
VDR in the gut, is aiding in the intestinal detoxification process and could thus reduce the 
occurrences of colon cancer, ulcerative colitis, and Crohn’s disease.137  
There are six phase II transformations: sulfation, glucuronidation, acetylation, 
methylation, glutathione conjugation and amino acid conjugation. Of these, we investigated 
sulfation, glucuronidation, and amino acid synthetic conjugation to CTA. Acetylation typically 
forms less polar compounds and does not affect the type of oxygen-containing functional groups 
found in CTA,138 so we excluded it along with methylating transformations.139 Glutathione 
conjugation by contrast is actually the first step in the generation of a set of several conjugated 
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metabolites.140 Because this transformation usually occurs with electrophilic groups not present 
in CTA, we did not investigate this conjugate.   
Sulfation, by contrast, is a very common enzymatic transformation that can occur with an 
alcohol group to form the corresponding sulfate. In humans, four families of sulfotransferases 
have been identified, nearly all of which use 3’-phosphoadenosine-5’-phosphosulfate (PAPS) as 
their cofactor.141 Steroids are common substrates for sulfotransferases, producing sulfates such 
as the estrogen sulfate conjugate.128 To investigate the sulfation of CTA in vivo, we synthesized 
both the mono-sulfate and the di-sulfate CTA conjugates as standards for identifying sulfo-CTA 
conjugates from tissues. 
Glucuronidation is one of the most common Phase II metabolic transformations, 
occurring in many different tissues including the liver, kidneys, and intestine. The transformation 
produces more water-soluble carbohydrate metabolites.130 Glucuronidation involves the 
conjugation of glucuronic acid, which is widely available as the enzyme cofactor uridine 5’-
diphosphate glucuronic acid (UDP-glucuronic acid). The enzymes responsible for this 
transformation are UDP-glucuronosyltransferases, a large class of cytosolic membrane-bound 
enzymes.142 Glucuronidation is arguably one of the most important processes in phase II 
metabolism, being the major elimination pathway for common xenobioitics, drugs, 
environmental toxins, and endogenous small molecules, e.g. steroids.130 We are currently 
investigating if glucuronides of CTA are formed in vitro and in vivo.  
We also synthesized the two amino acid conjugates of CTA which reflect the most 
common phase II amino acid conjugates: glycine and taurine. Both conjugations can be formed 
 
 
91 
 
 
in either liver or kidney. Conjugates generated in the liver are typically secreted as bile.143 The 
process of amino acid conjugation occurs in two steps. First, the ligation of the xenobiotic to 
acyl-CoA occurs by the corresponding ligase, followed by the formation of an amide bond with 
glycine by the enzyme glycine N-acyltransferase, or in the case of taurine, by the taurine N-
acyltransferase.144 In the case of CTA, it could be expected that these amino acid conjugates 
would act as bile acids, secreted into the intestines where they could be de-conjugated by 
microbes and reabsorbed.139  
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1.9 Synthetic Strategy for the Production of Calcitroic Acid Conjugates 
 
 
Synthesis of taurine CTA conjugate: 
 
In order to test out reaction conditions with a compound with similar characteristics and 
reactivity to CTA but less precious and commercially available, I began experimenting with 
taurine conjugation using the commercially available bile acid lithocholic acid (LCA). Initial 
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experiments used the Dayal et al. method,145 which was touted to be quick and effective using a 
conventional (non-scientific) microwave. If combining LCA, taurine, and EEDQ (coupling reagent) 
in dry ethanol and triethylamine (base) and microwaving in a water bath sounds unlikely to work 
to you, you would be right. After testing a few times using different setups, we moved on to a 
more reasonable synthesis from Tserng involving the same reagents but DMF instead of ethanol 
to increase solubility. The reaction was stirred at 90°C for 1 hour.146 The product was formed as 
determined by TLC, but the suggested isolation procedure, which involves pouring into the 
solution into a diethyl ether ice bath, would not be effective on the microscale on which we 
would be synthesizing tauro-CTA. We instead took a page from the Dayal reaction and used 
ethanol for the solvent, otherwise following the Tserng reaction conditions. This worked 
perfectly. Switching from LCA to CTA after that successful reaction provided the corresponding 
product with no further complications. After filtering of the insoluble leftover taurine, we could 
simply dry off the ethanol. The reaction could then be taken up in a minimum amount of water 
and the highly nonpolar byproducts extracted away with toluene. What remained was TEA and 
product. After trying to remove the large amount of remaining TEA by several methods including 
high vacuum, extraction, and azeotropic distillation to no success, we realized that it was forming 
a strong ion-pairing with the sulfonate. Therefore, we used solid phase extraction (SPE) to 
remove TEA by flushing the loaded crude product with a saturated sodium chloride solution 
(brine) until the TEA eluted. The salt on the cartridge could then be washed away with DI water 
and the product was eluted in 30% methanol in water. Upon evaporation under reduced 
pressure, the brown Cl— taurine salt conjugate was isolated in high purity. The detailed 
procedure can be found in the experimental procedure section.  
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Synthesis of glycine CTA conjugate: 
Initially, we attempted the synthesis of the glycine conjugate using LCA to test the 
method previously established by Incerti et al.,147 which uses N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (EDCI) as the coupling reagent and N-methyl morpholine 
(NMM) as the base to attach O-methylated L-glycine to the LCA acid functionality by stirring in 
DCM at room temperature overnight. This was followed by deprotection of the ester under basic 
conditions. The procedure worked as expected for the LCA. However, the reaction failed when 
we attempted it with CTA. CTA did not dissolve in DCM to the extent that the reaction could 
proceed, and only trace amounts of product were recovered. We made further attempts in THF 
and pyridine, which were also unsuccessful, before deciding we needed more than just solvent 
changes. 
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Therefore, we started with the O-Bis-silylated CTA and hydrolyzed it. This reaction was 
simple and effective in methanol/water that was adjusted to properly dissolve the starting 
material. NaOH was added up to 10% w/v, and the reaction stirred at room temperature for 
three hours until it was complete. The mixture was evaporated, redissolved in water followed by 
extraction with DCM giving the pure acid after evaporation.  
The O-Bis-silylated CTA was able to dissolve completely in DCM; however, very small 
scale (1-2mg) reactions were not forming the anticipated amide. After experimenting with LCA 
again, we discovered that the proportions of the reagents were very important: the ratios of 
NMM, EDCI, and the glycine methyl ester needed to be 9:4:4 respectively. Thus, reactions with 
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only a milligram or two of CTA and 40-80mg of the other materials would still form the ester 
after one hour at room temperature as long as the proportions between the other reagents 
were correct.  
 
The deprotection of the silyl groups, initially attempted with TBAF, was a clean reaction 
by TLC, but it was impossible to separate the product from the leftover TBA. After several 
attempts that included washing with NH4Cl to dissolve away the salt, extracting using many 
different solvents, column chromatography, ion-exchange resin,148 precipitating as a 
perchlorate,149 and using KF as an alternative F— source, we found an alternate TBS deprotection 
method used by Nakabayashi et al.150, one of the world’s premier laboratories focused on the 
synthesis of secosteroidal vitamin D analogues. Their group employed the use of 
camphorsulfonic acid (CSA) to remove TBS groups in a speedy (~15 min) reaction in dry methanol 
at room temperature. Of note is that running the reaction with stoichiometric amounts of CSA 
was unsuccessful or at best very slow, and the product as it turns out degrades very quickly in 
acid. However, with excess (6 eq) of CSA, the reaction was very quickly complete. The 
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degradation problem was ameliorated by swiftly quenching the completed reaction with enough 
NaHCO3 to neutralize the CSA, immediately concentrating it to get rid of the methanol, and then 
extracting the product with EtOAc. Immediate column chromatography and concentration of 
purified product gave the best yields.  
The hydrolysis to the glycine conjugate was a clean reaction, where the final precipitated 
product was pure provided it was not left long in acid. The reaction in water and methanol with 
up to 15% NaOH w/v was complete in 10 minutes. After evaporating off all methanol, the 
residue was dissolved in a minimum amount of water in a small Eppendorf tube, and the pH was 
adjusted HCl until the solution was just acidic (pH 1). The Eppendorf tube was quickly centrifuged 
to collect the white, grainy precipitate, which was dried overnight under high vacuum. The 
precipitate was then loaded on an SPE cartridge to remove salt impurities by washing with 
water, then eluted in a gradient from water to methanol (product came off between 40-50% 
methanol). Product was then quickly dried down, and purity was confirmed by NMR. The 
detailed protocol can be found in the experimental section. 
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Synthesis of bis-sulfate CTA conjugate: 
 
We used the sulfation method previously established in our lab, which had been used to 
make the LCA-sulfate conjugate. After testing the reaction conditions with both LCA and 
ergocalciferol, we tried the same method with CTA. In this reaction, H2SO4 and acetic anhydride 
were lightly heated to dissolve everything in pyridine, and then CTA was added. The reaction was 
complete after about ten minutes, and it was then cooled to 0°C, quenched with 25% NH4OH in 
water, stirred for 15 minutes, filtered, and concentrated. The crude mixture was then loaded on 
an SPE column, washed with pure water, and then eluted with up to 30% methanol in water. The 
di-sulfonated CTA conjugate was pure by NMR, and no further purification was necessary. 
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Synthesis of mono-sulfate CTA conjugate:  
In contrast to the bis-sulfated conjugate, very specific measurements are needed in this 
reaction to maximize the amount of mono-sulfate produced and minimize the bis-sulfate 
byproduct, which readily occurs with any sulfuric acid in excess of 1:1 proportions. As such, we 
prepared a solution of 0.5M H2SO4/1.0M acetic anhydride in pyridine and combined it with CTA 
to make a solution of 1:1:2 CTA:H2SO4:acetic anhydride proportions. No heat is necessary in this 
reaction because the sulfuric acid is dilute enough to stay in solution at room temperature. The 
reaction is complete within a half hour. Even with a 1:1 stoichiometry both mono and bis-
sulfated CTA were formed. The completed reaction was quenched with 25% aqueous NH4OH, 
concentrated, loaded onto an SPE cartridge, and eluted using an incremental gradient in order to 
separate the bis-sulfate from the mono-sulfate. The bis-sulfate eluted up to 25% MeOH in water, 
with the mono-sulfate eluting up to 35% MeOH in water.  
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1.10 Characterization of Calcitroic Acid Conjugates 
 
 
The CTA used in these syntheses was generated following the procedures described in 
Chapter 1.6. All moisture and/or oxygen-sensitive reactions were carried out under a dry 
nitrogen atmosphere. Reaction temperatures refer to the containing bath temperatures. 
Reactions were monitored by thin-layer chromatography (TLC) using Merck 60 UV254 silica gel 
plates. Visualization was performed with UV light, cerium molybdate general stain followed by 
heating, and other methods as noted. Synthesized compounds were purified by normal phase 
flash chromatography (SPI Biotage, silica gel 230-400 mesh) or solid phase extraction (Waters 
Sep-Pak C18 6cc Vac cartridge) except where noted. Mass analysis was performed using a 
Shimadzu 2020 LC-MS (single quadrupole) instrument and exact mass analysis was performed 
using a Shimadzu LCMS-IT-TOF. NMR spectra were recorded on a Bruker Avance 500MHz 
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instrument with compounds dissolved in the specified deuterated solvent. Optical rotations were 
recorded using Jasco DIP-370 Digital Polarimeter instrument in LCMS grade chloroform or 
methanol. 
 
Tauro calcitroic acid: To a stirred solution of CTA (45.6mg, 
0.123mmol) in ethanol (1.25mL) was added N-
ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (75mg, 
0.30mmol), taurine (30mg, 0.24mmol), and triethylamine 
(75μL, 0.54mmol). The reaction was refluxed for 1 hour, 
then removed from heat and filtered. The filtrate was concentrated and the residue taken up 
into a minimal amount of water (5mL), then extracted with toluene (2x5mL). The aqueous layer 
was then loaded onto an 500mg Sep-Pak Vac 6cc C18 cartridge and eluted in a gradient from 
brine to methanol (brine:MeOH 1:1). Fractions containing product were concentrated, then 
desalted using a second cartridge (water:methanol 7:3) to yield tauro-calcitroic acid as a yellow 
solid (20.4mg, 37%); Rf 0.14 (CHCl3 : MeOH 7 : 3); 1H-NMR (500MHz, CDCl3) δ 0.49 (s, 3H), 0.87 
(d, J = 6.25 Hz, 3H), 1.21-1.32 (m, 3H), 1.34-1.53 (m, 4H), 1.57-1.68 (m, 2H), 1.72-1.96 (m, 7H), 
1.96-2.02 (m, 1H), 2.22 (dd, J = 13.1, 7.6 Hz, 1H), 2.32-2.37 (m, 1H), 2.50-2.55 (m, 1H), 2.76-2.82 
(m, 1H), 3.01 (t, J = 6.9 Hz, 2H), 3.50 (t, J = 6.9 Hz, 2H), 4.07-4.13 (m, 1H), 4.33-4.37 (m, 1H), 4.93 
(s, 1H), 5.25 (s, 1H), 6.00 (d, J = 11.3 Hz, 1H), 6.40 (d, J = 11.3 Hz, 1H); 13C-NMR: (125MHz, CDCl3) 
δ 11.2, 18.5, 21.7, 23.1, 27.2, 28.6, 34.4, 35.0, 39.8, 41.1, 43.1, 44.0, 45.9, 49.7, 55.8, 56.1, 66.3, 
NH
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H
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70.5, 112.6, 116.7, 123.9, 134.4, 144.9, 146.5, 176.8; m/z calculated for C25H38NO6S 480.2340 
[M]—, found 480.2333; [𝛼]𝐷
25 = + 0.70 (c 1.0, MeOH) 
O-bis-silylated glyco calcitroic methyl ester: To a stirred solution 
of O-bis-silylated CTA (93 mg, 0.15mmol), glycine methyl ester 
hydrochloride (43mg, 0.35mmol), and N- methyl morpholine 
(87.5μL, 0.88mmol) in dry DCM (10mL) was added 1-ethyl-3-(3-
dimethylaminopropryl)carbodiimide (66mg, 0.35mmol). The 
reaction was allowed to stir for two hours at room 
temperature. The reaction mixture was quenched with 10mL of 2M HCl, extracted with DCM 
(10mLx3), and the combined organic layers were washed with brine. The organic layers were 
dried over MgSO4 and concentrated to the O-bis-silylated glyco calcitroic methyl ester (93mg, 
90%) as a clear oil. No attempts were made to purify the product further: Rf 0.21 (DCM); 1H-NMR 
(500MHz, CDCl3) δ 0.08 (s, 12H), 0.58 (s, 3H), 0.89 (s, 18H), 1.02 (d, J = 11.0 Hz, 3H), 1.30-1.40 
(m, 3H), 1.44-1(m, 3H), 1.6-1.71 (m, 2H), 1.75-1.83 (m, 1H), 1.83-2.06 (6H), 2.23 (dd, J = 24.0, 
12.5 Hz 1H), 2.42-2.52 (m, 2H), 2.79-2.88 (m, 1H), 3.78 (s, 3H), 4.08 (d, J = 8.5 Hz, 2H), 4.16-4.26 
(m, 1H), 4.38 (dd, J = 10.5, 5.9 Hz, 1H), 4.87 (d, J = 3.7 Hz, 1H), 5.19 (d, J = 2.6 Hz, 1H), 5.94-6.07 
(m, 2H), 6.25 (d, J = 18.8 Hz, 1H); 13C-NMR: (125MHz, CDCl3) δ –5.1, –4.8, –4.69, –4.67, 12.0, 
18.1, 18.2, 19.5, 22.1, 23.4, 25.8 (3C), 25.9 (3C), 27.8, 28.8, 34.5, 40.5, 41.2, 43.7, 44.8, 45.9, 
46.1, 52.3, 56.3, 56.5, 67.5, 72.1, 111.3, 118.1, 123.1, 135.2, 140.6, 148.3, 170.6, 173.1; m/z 
calculated for C38H67NO5Si2 674.4631 [M + H]+, found 674.4564 
 
O
H
OTBSTBSO
NH
O
O
 
 
105 
 
 
 
 Glyco calcitroic methyl ester: To a solution of O-bis-silylated glyco 
CTA methyl ester (49mg, 0.073mmol) in dry methanol (3.6mL) 
was added camphorsulfonic acid (102mg, 0.439mmol). The 
reaction was monitored closely and quenched with NaHCO3 (2mL) 
afte r 25 minutes. The reaction mixture was concentrated under 
reduced pressure and the aqueous layer was extracted with DCM 
(3x2mL). The combined organic layers were dried with MgSO4, concentrated, and purified by 
column chromatography (MeOH : EtOAc 1:15) to yield glyco calcitroic methyl ester (25mg, 65%) 
as a fluffy white powder; Rf 0.41 (EtOH: EtOAc 1:7); 1H-NMR (500MHz, CDCl3) δ 0.59 (s, 3H), 1.02 
(d, J = 10.0 Hz, 3H), 1.27-1.41 (m, 3H), 1.43-1.60 (m, 3H), 1.63-1.72 (m, 2H), 1.72-1.83 (m, 3H), 
1.83-2.04 (m, 6H), 2.32 (dd, J = 22.4, 10.8 Hz, 1H), 2.44 (d, J = 21.8 Hz, 1H), 2.60 (d, J = 22.0 Hz, 
1H), 2.84 (d, J = 21.1 Hz, 1H), 3.77 (s, 3H), 4.06 (d, J = 8.1 Hz, 2H), 4.24 (s, 1H), 4.44 (s, 1H), 5.01 
(s, 1H), 5.34 (s, 1H), 5.97-6.07 (m, 2H), 6.38 (d, J = 18.7 Hz, 1H); 13C-NMR: (125MHz, CDCl3) δ 
12.1, 19.4, 22.3, 23.5, 27.7, 29.0, 34.4, 40.4, 41.2, 42.9, 43.6, 45.3, 46.0, 52.4, 56.3, 56.6, 66.8, 
70.8, 111.8, 117.3, 124.8, 133.2, 142.7, 147.7, 170.6, 173.0; m/z calculated for C26H39NO5 
446.2901 [M + H]+, found 446.2851; [𝛼]𝐷
25 = —4.0 (c 1.0, CHCl3)  
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Glyco calcitroic acid: To a stirred solution of glyco CTA methyl 
ester (20.2mg, 0.045mmol) in a minimum of MeOH (0.9mL) was 
added 1.8 mL of 15% w/v NaOH in H2O. The reaction was 
completed in 10 minutes. Methanol was removed under reduced 
pressure and the reaction mixture was dissolved in a minimum of 
water. The reaction mixture was acidified and precipitated with 
concentrated HCl to pH 2, then centrifuged and the precipitate collected by decanting the 
supernatant and drying the remaining solid under reduced pressure. The crude solid was 
desalted and purified using 500mg Sep-Pak Vac 6cc C18 cartridges (50% methanol/water) to 
yield an off-white solid (7.3mg, 39%): Rf 0.53 (MeOH : EtOAc 3:2); 1H-NMR (500MHz, D2O) δ 0.50 
(s, 3H), 0.89 (d, J = 6.45, 3H), 1.20-1.35 (m, 3H), 1.35-1.55 (m, 4H), 1.58-1.68 (m, 2H), 1.74-1.97 
(m, 6H), 1.97-2.03 (m, 1H), 2.23 (dd, J = 13.1, 7.5 Hz, 1H), 2.40 (dd, J = 13.8, 3.6 Hz, 1H), 2.50-
2.55 (m, 1H), 2.76-2.82 (m, 1H), 3.75 (dd, J = 27.0, 17.5 Hz, 2H), 4.07-4.12 (m, 1H), 4.34-4.37 (m, 
1H), 4.94 (s, 1H), 5.25 (s, 1H), 6.01 (d, J = 11.3 Hz, 1H), 6.41 (d, J = 11.3 Hz, 1H); 13C-NMR: 
(125MHz, MeOD) δ 11.2, 18.6, 19.3, 22.0, 23.2, 27.4, 28.6, 34.2, 40.5, 42.9, 43.0, 43.6, 45.2, 
45.7, 56.3, 65.9, 70.0, 110.4, 118.0, 123.0, 135.5, 140.2, 149.3, 174.2, 175.9; m/z calculated for 
C25H37NO5 432.2744 [M + H]+, found 432.2680; [𝛼]𝐷
25 = + 24.0 (c 1.0, MeOH) 
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Bis-sulfo calcitroic acid: A solution of H2SO4 (160μL) and acetic 
anhydride (280μL) was stirred in pyridine at 55°C for 5 
minutes. When everything was solubilized, a solution of CTA 
(43.1mg, 0.115mmol) was added. The solution was stirred for 
approximately ten minutes while monitoring by TLC, then 
removed from heat and cooled to 0°C. To the cooled solution was added 25% aqueous NH4OH 
(840μL). The solution was stirred for 5 minutes, filtered over a pad of celite followed by 
evaporation. The crude residue was then loaded on an SPE cartridge, washed with water, 
purified in a gradient up to 30% methanol in water, and then concentrated to the bis-sulfated 
CTA as a white powder (18.4mg, 30.0%); Rf 0.18 (MeOH : EtOAc 3:7); 1H-NMR (500MHz, CDCl3) δ 
0.63 (s, 3H), 1.04 (d, J = 6.2 Hz, 3H), 1.32-1.41 (m, 3H), 1.45-1.52 (m, 1H), 1.54-1.63 (m, 2H), 
1.66-1.74 (m, 2H), 1.88-1.96 (m, 3H), 2.01-2.08 (m, 3H), 2.22-2.29 (m, 1H), 2.30-2.36 (m, 1H), 
2.42-2.48 (m, 1H), 2.57 (dd, J = 13.7, 6.7 Hz, 1H), 2.67-2.72 (m, 1H), 2.85-2.91 (m, 1H), 4.77-4.83 
(m, 1H), 5.00-5.06 (m, 2H), 5.47-5.50 (m, 1H), 6.12 (d, J = 11.1 Hz, 1H), 6.38 (d, J = 11.1 Hz, 1H); 
13C-NMR: (125MHz, CDCl3) δ 11.0, 18.7, 21.8, 23.2, 27.2, 28.6, 33.8, 36.6, 40.3, 41.0, 41.9, 45.6, 
56.2, 56.3, 73.9, 76.7, 113.2, 117.7, 124.5, 132.8, 141.6, 143.7, 176.0; m/z calculated 533.1532 
[M]— and 266.0783 [M]2—, found 533.1426 and 266.0674; [𝛼]𝐷
25 = —18.0 (c 1.0, MeOH) 
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Mono-sulfo calcitroic acid: A solution of H2SO4 (0.5M) and 
acetic anhydride (1M) in pyridine was prepared. To a stirred 
solution of CTA (19.8mg, 0.053mmol) in pyridine (0.5mL) at 
room temperature was added 105.7μL of the prepared 
solution (0.053mmol H2SO4; 0.106mmol acetic anhydride). 
The reaction was monitored for a half hour and quenched with 25% aqueous NH4OH (200μL). 
The solution was stirred for 5 minutes and concentrated. The crude residue was then loaded on 
an SPE cartridge, washed with water, purified in a gradient up to 60% methanol in water, and 
concentrated to a clear oil (8.99mg, 37.5%); Rf 0.47 (MeOH : EtOAc 3 : 7); 1H-NMR (500MHz, 
CDCl3) δ 0.64 (s, 3H), 1.04 (d, J = 6.2 Hz, 3H), 1.30-1.42 (m, 3H), 1.43-1.64 (m, 4H), 1.66-1.75 (m, 
2H), 1.82-2.00 (m, 5H), 2.02-2.09 (m, 2H), 2.29-2.36 (m, 1H), 2.43-2.48 (m, 1H), 2.55-2.66 (m, 
2H), 2.86-2.91 (m, 1H), 4.34-4.39 (m, 1H), 4.79-4.84 (m, 1H), 4.92-4.95 (m, 1H), 5.34-5.38 (m, 
1H), 6.10 (d, J = 11.2 Hz, 1H), 6.34 (d, J = 11.2 Hz, 1H); 13C-NMR: (125MHz, CDCl3) δ 10.9, 18.7, 
21.9, 23.2, 27.3, 28.5, 33.9, 40.3, 40.4, 41.0, 41.5, 41.9, 45.6, 56.1, 56.2, 68.8, 74.3, 109.6, 117.6, 
123.6, 133.9, 141.0, 148.5, 176.1; m/z calculated 453.1958 [M]— , found 453.1867; [𝛼]𝐷
25 = —
18.0 (c 1.0, MeOH) 
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1.11 A Brief Biological Characterization of Calcitroic Acid Conjugates 
 
 
The four conjugates of CTA, which were synthesized using the methods described in 
Chapter 1.10, were evaluated with different biochemical assays to determine their biological 
activity. We used fluorescence polarization to determine the binding of these compounds 
towards VDR and a transcription assay with HEK293 kidney cells to determine if these conjugates 
modulate the transcription of P450 enzyme CYP24A1. Furthermore, we treated macrophages 
(RAW264.7) with the CTA conjugated to determine possible anti-inflammatory properties.   
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Binding to VDR using fluorescence polarization 
Using the same method described in Chapter 1.7, recombinant VDR-LBD was incubated 
in the presence of fluorescently labeled SRC2-3 peptide VDR agonist LG190178 and increasing 
concentrations of CTA conjugates and calcioic acid. As shown in Figure 32, calcioic acid disrupts 
the interaction between the agonist and VDR with an IC50 of 71μM. All CTA conjugates were able 
to compete with LG190178, albeit with IC50 values higher than 92μM.  
 
 
 
 
 
 
 
 
Interaction with VDR using a transcription assay 
Using the same method described in Chapter 1.7, HEK293T cells were transfected with 
CMV-VDR plasmid for overexpression of VDR and the reporter plasmid of a luciferase gene under 
the control of a CYP24A1 promoter. In the presence of VDR agonists, induction of the luciferase 
gene occurs. This produces luciferase, which in the presence of luciferin substrate generates a 
proportional bioluminescence signal. As shown in Figure 33, CTA glycine was the only CTA 
Figure 32: Binding curves for conjugates by FP analysis. EC50 values: calcioic 
acid (71 ± 4 μM), CTA taurine (145 ± 25 μM), CTA glycine (92 ± 17 μM), CTA 
mono sulfate (92 ± 5 μM), CTA bis sulfate (139 ± 20 μM). 
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conjugate that exhibited an agonist behavior with an EC50 of 49μM for the measured 
concentration range. Calcioic acid was not able to induce VDR-mediated transcription but rather 
showed some antagonistic behavior.  
 
 
Effect of CTA conjugates on macrophages 
Using a Griess assay, the released NO concentration from activated RAW264.7 cells was 
measured in the presence of CTA conjugates. This assay was introduced in Chapter 1.7 and the 
results are summarized in Figure 34. Interestingly, all of the CTA conjugates and calcioic acid 
showed a significant reduction of nitric oxide production at 12.5μM (Figure 34A). Positive control 
compound dexamethasone at 100nM showed a similar effect. The reduction of NO in the 
Figure 33: Transcription activation of CTA and its conjugates and 
related compounds, shown as percentages of full calcitriol activation 
at 60nM. EC50 of CTA taurine is 49 ± 21 μM.  
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presence of 25μM and 50μM CTA glycine was the most pronounced among all other CTA 
conjugates (Figure 34B&C).  
In parallel, we investigated a possible toxic effect that could lead to a reduction of NO 
production. Therefore, we determined the viability of these macrophages under the same 
condition using Cell-Titer Glo. The results are summarized in Figure 35. For CTA conjugate 
concentrations of up to a 100μM, no reduction of cell viability was observed.  
 
  
Figure 35: Toxicity assay for macrophages. No toxicity was seen up to 100μM for 
any of the compounds 
Figure 34: Significant deviation from stimulated macrophage (DMSO-treated) NO production seen at 12.5μM, with trends 
increasing in significance at higher concentrations 
A B C 
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Discussion 
Based on the defined VDR binding pocket for VDR agonists that was elucidated by X-ray 
crystallography, it was not anticipated that any of the CTA conjugates would interact with VDR or 
induce a VDR-mediated effects even at very high concentrations. Our results however confirmed 
that these compounds at concentrations of 60μM and higher can interact with VDR. CTA glycine 
was the only CTA conjugate showing an agonistic VDR-mediated effect at concentrations of 
15μM and higher. Furthermore, we confirmed with the agonistic effect of CTA glycine that this 
compound is cell-membrane permeable.  
The CTA-related compound calcioic acid, however, was expected to bind to VDR, albeit at 
higher concentrations than CTA because of its missing 1α-hydroxyl group. We were able to 
confirm this hypothesis. However, the interaction between calcioic acid and VDR did not result in 
any appreciable induction of transcription at a concentration of 100μM.  
When macrophages were treated with CTA conjugates, a decrease in nitric oxide 
production at 12.5μM and greater concentrations was observed. While no cell death was 
apparent by our Cell-Titer Glow viability assay at any concentration, the possibility exists that 
general protein production was compromised at these high concentrations of CTA conjugates 
that in turn reduced the formation of NO. The only evidence that the reduction of NO formation 
is linked to VDR in this study is the behavior of CTA glycine that showed activation of VDR-
mediated transcription and a very pronounced reduction of NO production. Similar effects were 
described for CTA before. Assessing the toxicity of these conjugates using other metrics than ATP 
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quantification (Cell-Titer Glo) will be carried out in the future to further investigate the anti-
inflammatory effect of vitamin D metabolites.   
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Experimental Procedures: 
Fluorescence Polarization Binding Assay Protocol 
The FP assay buffer was prepared by adding 25mM PIPES (piperazine-N,N’-bis(ethanesulfonic 
acid, Sigma-Aldrich), 50mM NaCl (Fisher), and 0.01% NP-40 detergent to 18.2MΩ water. The 
buffer was filtered and adjusted to pH 6.75. To this was added 7.5nM of the coactivator peptide 
SRC2-3 (CKKKENALLRYLLDKDDTKD) which had been labeled with cysteine-reactive AlexaFluor647. 
To this solution was added 500nM of VDR-LBD, which had been expressed and purified as 
reported previously.120 The VDR agonist LG190178, which had been synthesized previously 
according to a published protocol,121-122 was added at a concentration of 600nM. A 20mM stock 
of each CTA conjugate in DMSO was serially diluted (1:2) in a 384-well plate (Corning, CLS3702). 
To a 384-well black polystyrene microplate (Corning, CLS3658), 20μL of the prepared VDR-LBD 
assay solution was dispensed to test against the CTA conjugates’ serial dilution. Using the Tecan 
Freedom EVO liquid handler system and a 100nL pin tool (V&P Scientific), a total of 100nL of 
each CTA conjugate concentration was transferred in quadruplicate to the 20μL assay solution for 
a final maximum concentration of 100μM of each conjugate. Following incubation for 1 hour, 
fluorescence polarization was detected at an excitation/emission wavelength of 635/685 nm 
using the Tecan Infinite M1000 plate reader.  
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Transcription Assay Protocol 
Human embryonic kidney (HEK293, ATCC CRL-3249) T cells were cultured in DMEM/High 
Glucose (Hyclone, #SH3024301) with non-essential amino acids (Hyclone, #SH30238.01), 10 mM 
HEPES (Hyclone, #SH302237.01), 5 x 106  units of penicillin and streptomycin (Hyclone, 
#SV30010), and 10% of FBS (Gibco, #10082147). Transfection was carried out with 70-80% 
confluent cells. For VDR transfection, 2 mL of untreated DMEM/High Glucose media containing 
0.7 μg of VDR-CMV plasmid, 16 μg of a CYP24A1-luciferase reporter gene, LipofectamineTM LTX 
(75 μl, Life Technologies #15338020), and PLUSTM reagent (25 μl) was added to the flask. After 
16 hours of incubation at 37oC with 5% CO2, the cells were harvested with 3mL of 0.05% Trypsin 
(Hyclone, #SH3023601), added to 10mL of the assay buffer (DMEM/High Modified buffer 
without phenol red, Hyclone #SH30284.01) and spun down for 2 minutes at 1000 rpm. The 
media was removed and cells were resuspended in the DMEM assay media. Prior to adding cells 
to sterile white, optical bottom 384-well plates, plates were treated with 20 μL per well of a 
0.25% matrigel solution. To each well, 20μL of cells were added to yield a final concentration of 
15,000 cells per well. The plates were then spun down for 2 minutes at 1000 rpm. After four 
hours, plated cells were treated with 100 nL of compounds and controls which were added using 
the EVO liquid handling system with a 100nL pin tool (V&P Scientific). Controls used with VDR 
were 1,25(OH)2D3 (10 nM in DMSO, Endotherm) and DMSO. After 16 hours of incubation at 37oC 
with 5% CO2, 20μL of Bright-Glo™ Luciferase Assay Kit (transcription assay, Promega, Madison, 
WI) were added and luminescence was read on the Tecan Infinite M1000 reader.   
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Griess Assay Immune Modulation Protocol 
The murine macrophage cancer cell line RAW264.7 was cultured in DMEM (ATCC 30-2002) with 
10% FBS. To initiate an immune response, cells were suspended at a cell density of 1x106 
cells/mL and a control sample (80μL x 8) was dispensed into a 384-well clear-bottomed sterile 
plate with a lid (Nunc 142762). The remaining suspended cells were then activated with 
interferon gamma (IFNγ, 150units/mL) and lipopolysaccharide (LPS, 50ng/mL). Activated cells 
were dispensed into a 384-well plate (80μL/well). A dose-response 384-well plate (highest 
concentration each: 100mM) of the compounds of interest was then used to dose the activated 
cell plate with 100 nL using the EVO liquid handling system with a 100nL pin tool (V&P Scientific) 
for a final highest concentration in the assay plate of 100μM. Each concentration was tested in 
quadruplicate. The following controls were also dosed in octuplicate: activated cells with only 
DMSO, dexamethasone (1μM), and the toxic compound CBT (10μM). The dosed cells were then 
allowed to incubate for 24 hours. 
Following incubation, aliquots of supernatant (40μL) from each well were moved to a separate 
384-well clear-bottomed plate with a lid (CLS3700). To each aliquot was added 40μL of 
sulfanilamide solution (Promega Griess Reagent System, TB229). The covered plate was shaken 
briefly and incubated in the dark for 10 minutes. Following this, 40μL of NED solution (Promega 
Griess Reagent System, TB229) was added to each aliquot. The plate was incubated in the dark 
for 10 minutes. The absorbance of the plate was then read on the Tecan Infinite M1000 plate 
reader (530nm).  
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To the remaining 40μL of dosed cells and media was added 40μL of Cell Titer Glow luminescent 
cell viability assay (Promega, G7572). The plate was shaken for 20 minutes and the luminescence 
then read on the Tecan Infiniate M1000 plate reader.  
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PART II: TOWARD THE DEVELOPMENT OF A NOVEL ORALLY-AVAILABLE ASTHMA 
TREATMENT TARGETING GABAA RECEPTORS IN THE LUNGS 
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2.1 A Brief Introduction to Asthma  
 
 
The treatment and control of asthma remains a persistent modern clinical problem, 
despite being recognized for decades and occurring all across the globe.10 An estimated 300 
million people have asthma worldwide, including nearly 40 million in the United States.14 Its 
prevalence is expected to continue to rise. The central hallmarks of asthma are chronically 
inflamed airways, hypersensitivity to certain external stimuli, and obstruction of the airways.11 
These characteristics lead to clinical features that include persistent cough, shortness of breath, 
wheezing, coughing, and chest tightness.12  
As a long-term disease affecting both children and adults, solutions for effective 
treatment remain limited. The first line of chronic therapy is based on long-acting β2 adrenergic 
receptor agonists with or without anti-inflammatory corticosteroids delivered with an inhaler.14 
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Some cases of chronic asthma are able to be controlled using this method, and it does have the 
advantage of providing a targeted delivery to the bronchial submucosa, thus avoiding the 
systemic effects of corticosteroids delivered orally.151 However, the expected disadvantages due 
to imprecise dosing and poor compliance are ubiquitous, and sometimes lead to loss of control 
over the asthmatic symptoms.151 In more severe cases, asthmatic symptoms are treated 
systemically with corticosteroids. These treatments can cause adverse side effects that include 
growth suppression, thinning of the skin or excessive bruising, formation of cataracts, adrenal 
suppression, and increased mortality.15-19 An alternative oral treatment exists in the form of a 
leukotriene receptor antagonist (Montelukast) for those who do not respond well to other 
methods;152 however, this treatment has a low success rate (somewhere between 35% and 78% 
of patients do not respond to it).153 It is believed that genetic variations in leukotriene signaling 
are responsible for this alternative therapy being inefficacious.153 A final treatment option is 
injectable biological treatments such as the mlgE-expressing B lymphocyte-specific monoclonal 
antibody omalizumab,154 or the interleukin-5-specific monoclonal antibody mepolizumab for 
eosinophilic asthma.155 However, with patient costs for such treatments up to $30,000 a year 
and the risk for anaphylaxis up to 0.2% with omalizumab,154 the widespread use of these 
treatments is limited to only the most severe cases.  
Our laboratory, in collaboration with the Cook laboratory at UWM, is seeking an alternate 
therapy to combat multiple symptoms associated with living with acute asthma.1, 13 There are 
several factors upon which current treatments could be improved: (1) A better asthma drug 
alternative should be orally administered to improve patient compliance and eliminate dosage 
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irregularity. (2) Furthermore, unwanted central nervous system effects should be avoided at all 
cost. (3) Finally, the alternative drug should alleviate a full range of asthma symptoms, such as 
relaxing the smooth muscle constriction and decreasing inflammation in the airways, rendering 
combination treatments obsolete.20 
Central to achieving those goals is a new therapeutic target for asthma, which is the 
family of gamma-aminobutyric acid A receptors (GABAAR). GABAARs are ligand-gated chloride ion 
channels, whose primary function is to regulate intracellular chloride concentrations, especially 
in neurons. The GABAARs consists of five subunits combined into a heteropentamer. A typical 
GABAAR on neurons consists of two alpha, two beta, and one “other” subunit out of the 19 
known subunits (α1-6, β1-3, γ1-3, δ, ε, π, θ, ρ1−3).21 Recently, GABAARs have been identified on 
airway smooth muscle cells, airway epithelia cells, and inflammatory cells.1, 24, 156-160 These cell 
types contain α4 and α5 subunits.24 In recent decades, the Cook group has introduced subtype-
selective GABAAR ligands based on the benzodiazepine scaffold.22 Further investigations have 
shown that these ligands mediate distinct pharmacological properties including relaxation of 
airway smooth muscle and anti-inflammation. Proof of concept that GABAAR ligands can alleviate 
asthma symptoms was first shown with plant-based positive allosteric modulator honokiol by 
Munroe et al.23 Our group has since developed imidazobenzodiazepine-based compounds that 
target relevant GABAAR subtypes expressed in the lung with pronounced efficacy in several 
asthmatic mouse models.1, 13, 20, 24 Achieving targeted asthmatic relief with oral medication and 
thus eliminating the use of corticosteroids is seen as a huge step forward in asthma treatment. 
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2.2 Mucin Volume Density as a Marker of Asthmatic Disease State 
 
 
Embedded within the epithelial layer of the bronchi, 
larger bronchioles, and trachea are goblet cells.161 Their role 
is to maintain the protective mucus membrane, which they 
do by secreting mucins: large glycoproteins consisting 
mainly of carbohydrates (Figure 36).161 The bound 
carbohydrates attract appreciable amounts of water, giving 
the mucin layer a jelly-like consistency and allowing surfaces to stay well-lubricated. The 
essential protective role that mucins play keeps the surfaces of the lungs clean, as it immobilizes 
stimulants like dust particles and bacteria. The cilia of the epithelial cells covered by the mucins 
Figure 36: Goblet cells adopted from 
https://www.histology.leeds.ac.uk 
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beat the secretions and direct contaminants up out of the lungs, while the goblet cells continue 
to produce more mucins as needed to replenish the mucous membrane.161  
In the asthmatic disease state, goblet cells are overrepresented.162 This can be due to the 
caused by the goblet cells dividing too often, known as goblet cell hyperplasia, or by too many 
epithelial cells differentiating into goblet cells, known as mucus metaplasia.163 Both processes 
create too many mucins, and both are known to occur in asthma. This excess of secretions 
causes a dense, thick mucus layer that cannot be thinned out or removed in the usual manner by 
cilia movement or even by coughing. Combined with the other classical asthma symptoms such 
as constriction of the airways, the danger of clogging airways increases leading to asthma 
exacerbations.   
The purpose of this study was therefore to observe mucus overproduction in the 
epithelial layer of an asthmatic mouse model and monitor the effect of new asthma drug 
candidates.  
 
Experimental section 
Male BALB/c mice were injected i.p. with 50 μg ovalbumin adsorbed with 2 mg aluminum 
hydroxide (alum) in saline (0.9% NaCl) to sensitize them on day 0, 7, and 14 of a study. On days 
23-27, the asthmatic model was induced by challenging those mice intranasally with 25 μl of a 
0.4 mg/ml ovalbumin solution. Concurrently, mice in testing groups received an assigned dosage 
of small molecule, positive control compounds (β-agonists or Montelukast) or vehicle only as 
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negative control. The mice were then given a final administration of these compounds before 
euthanasia on day 28 followed by collections of tissues and fluids.   
For evaluating lung mucin volume density, a cannula was inserted into the trachea of the 
deceased mouse. The lungs were inflated with phosphate buffered saline to keep the airways 
from collapsing. The larger left lung was collected and put in 10% buffered formalin over night at 
4°C, followed by washes with 70%  ethanol and storage in 70% ethanol. The samples were send 
to Wisconsin Children’s Hospital for embedding and sectioning in paraffin. The lungs were 
sectioned as follows: held vertically, the lung was cut through the middle, side to side, so that 
the main axial airway was exposed as a circular disk. The primary concern during this process was 
that lungs could be mishandled or crushed so that the mucus layer dislocates. However, the 
presence of mucus secreted by goblet cell hyperplasia was consistent within every population 
surveyed. Two slides were made for every mouse lung that was collected (one utilized and one 
as a “backup” in case the first had problems, detailed below).  
The returned slides with lung sections were handled as follows:  
 
Preparation of solutions: 
 Fluorescent Schiff reagent solution: 0.75 g acriflavin HCl, 150 mL distilled water, 1.5 g 
sodium metabisulphite, and 1.5 mL of a 10M solution of HCl. The solution must be kept in 
the dark for 48 hrs 4°C before use. It will still decompose and stain much less brightly 
within a week, so small batches are recommended. 
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 1% periodic acid solution: 1 g periodic acid and 100 mL distilled water. This solution must 
be made fresh every time slides are stained. 
 Acid alcohol solution: 70mL ethanol, 29mL distilled water, and 1mL 10M HCl 
 Canada balsam mounting media: 50:50 Canada balsam and methyl salicylate 
 
Dewaxing and rehydration of slides: 
 Immersed in histoclear, 2x for 30 minutes; 
 Immersed in 100% ethanol, 2x for 5 minutes; 
 Immersed in 95% ethanol in water, 2x for 5 minutes; 
 Immersed in 80% and then 70% ethanol in water for 5 minutes; 
 Immersed in PBS, 2x for 5 minutes. 
 
Staining and preservation of slides: 
 Slides were oxidized in 1% periodic acid for 10 minutes; 
 Slides were rinsed with DI water, 3x for 5 minutes; 
 Slides were stained with fluorescent Schiff’s reagent for 20 minutes; 
 Slides were rinsed with DI water, 3x for 5 minutes; 
 Slides were rinsed with acid alcohol, 2x for 5 minutes; 
 Slides were air-dried in the dark. 
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 A few microliters of Canada balsam mounting media was placed on the section and the 
coverslip was tilted carefully over it in order to avoid trapping air bubbles and protect 
from disturbing the tissue. After leaving overnight, fixing is complete. The slides were 
then evaluated the following day to avoid loss of fluorescence.  
Image collection: Using an EVOS inverted digital 
fluorescence microscope (Thermo Fisher), the 
slides were carefully observed. The main axial 
airway forms a large unstained hole through the 
center of each lung section. Using the green 
fluorescent protein (GFP) filter, the epithelia of 
the axial airway was zoomed to 40X. The 
circumference was inspected to find areas that exhibited cells that were cut cleanly (ex: without 
many layers of epithelial cells apparent in the background, making the “surface” of the 
epithelium appear thicker than it really is) and a basement membrane free of “wrinkles.” The 
scale bar of 100 μm was displayed on each image for scaling purposes later. Images of these 
smooth, clean areas were taken, at a rate of exactly 4 per slide, spaced as much as was allowable 
around the axial airway. If four acceptable non-overlapping images were unable to be captured 
in a single sample, the “backup” slide was used instead. There were no cases wherein both slides 
failed to have four acceptable images taken.  
Images were taken using the GFP and the RFP (red fluorescent protein) filters on the 
same image, and the two were overlaid to form a single image that exhibits green epithelium 
Figure 37: Overlay of GFP and RFP filtered images of 
ovalbumin sensitized and challenged mouse airway 
epithelium 
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and basement tissue and red mucus in goblet cells (Figure 37). These raw images were saved as 
JPG files and carefully numbered and categorized for later processing.  
Processing procedure: Following the instructions of V. Kim et al,163 the images were opened with 
the ImageJ software. Images were resized (imageadjustsize) to 680w x 512h pixels. Next, 
the “straight line tool” was used to draw a line equal to the distance between the two points on 
the ends of the scale bar. This line then was used to scale the picture (analyze  set scale). The 
distance in pixels is displayed, and the length and units (100 um respectively) were entered. Note 
that once this scale is known, it can be entered directly into the “set scale” selection for future 
images.  
Next, the length of the basement membrane was measured. The ROI manager was 
opened (analyzetoolsROI manager). The “straight line tool” was used to draw lines along the 
basement membrane, hitting CTRL+D each time to make the line permanent (alternatively: 
editdraw). After each segment is drawn, hitting 
“T” adds it to the ROI manager (alternatively, 
clicking Add(t) in the ROI Manager window) (see 
Figure 38). When the basement membrane had 
been fully outlined, “measure” was clicked in the 
ROI Manager window. A new window pops up 
containing multiple fields with quantities 
concerning those lines. The “length” measurement 
Figure 38: Using ROI manager to quantify data 
concerning drawn line segments in airway epithelium 
image opened in ImageJ 
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is all that is needed, but it is easier to save the whole set than select just that piece of data. The 
whole set was saved, again carefully naming each one to reflect the image it came from.  
Next, the area of mucus was measured. Whatever measurements are in the ROI Manager 
were deleted. Then using the “freehand selection tool,” the circumference of an area of mucus 
was outlined. The tool automatically closes the area off if the beginning and ending of an area 
are not perfectly overlapped. As with the length measurements, after each area was finished, 
CTRL+D and “T” are hit to make the lines permanent and add them to the ROI Manager. Once all 
mucus areas were outlined, “measure” was clicked in the ROI Manager and the window that 
pops up with quantities concerning those areas was saved.  
This process was repeated for every image, which is why saving and naming them 
carefully is an essential part of this data collection. Once all quantities were acquired, they were 
consolidated. For each lung section, an Excel file was made. In that Excel file, the four images and 
their quantities were first separately considered. Columns for “Length,” “Total Length,” “Area,” 
“Total Area,” and “Mucin Volume Density” were made. For each of the four images, the 
measured “Lengths” from the saved length file were added to the “Length” column, and the 
measured “Areas” from the saved area file were added to the “Area” column. The “Total Length” 
and “Total Area” columns displayed the sum of those values (=SUM(x)). The “Mucin Volume 
Density” column uses the following equation:  
𝑡𝑜𝑡𝑎𝑙 𝑎𝑟𝑒𝑎
𝑡𝑜𝑡𝑎𝑙 𝑙𝑒𝑛𝑔𝑡ℎ
·
4
𝜋
= 𝑚𝑢𝑐𝑖𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑑𝑒𝑛𝑠𝑖𝑡𝑦                                            Equation 1 
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which converts the measured values (area density and length, effectively) into volume density. 
These quantities need to be separately evaluated for each image in each lung. The four Mucin 
Volume Densities were then averaged into a separate column for Mucin Volume Density Average 
(=AVERAGE(Mucin Volume Densities)). Secondary values of Mucin Volume Density Standard 
Deviation (=STDEV(Mucin Volume Densities)) and Standard Error (Standard Deviation/(3^0.5)) 
were also calculated. 
 
 
Results  
We have investigated the pharmacological effects of α4-selective GABAAR positive 
modulator (XHE-III-74EE)164 in an ovalbumin sensitized and challenged (Ova S/C) murine model 
of asthma that represents an acute allergic pulmonary inflammation model. The results were 
published in 2016 and are summarized in Figure 40.24  
Figure 39: (a) Representative control: vehicle-only mouse airway epithelium; (b) Representative positive control/treatments: 
ovalbumin sensitized and challenged mouse airway epithelium. Note that all mice tested with small molecules also had the 
same appearance; (c) Representative negative control: the corticosteroid dexamethasone decreased mucin quantities. 
B 
 
A 
 
C 
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Non-challenged mice treated with i.p. injection of vehicle twice a day for five days were 
used to determine the baseline levels of mucus produced by the mouse lung. Sensitization and 
challenge with ovalbumin, however, significantly increase in mucin volume density levels to 
almost 20 nL/mm2. When Ova S/C mice were injected for five days with 4 mg/kg/day of 
glucocorticoid dexamethasone, a significant reduction of the lung mucin volume density was 
observed. By comparison, XHE-III-74EE, when administered i.p. twice a day for five days at 20 
mg/kg neither increased nor decreased the mucin volume density. A single i.p. injection of XHE-
III-74EE 40 minutes before euthanasia showed that acute dosage also had no effect on mucin 
volume density. To study a continuous release model of XHE-III-74EE, mini-pumps were 
deposited under the skin on the back of the animals. The continuous application of vehicle 
resulted in a mucin volume density similar to that of the vehicle i.p. injection. The continuous 
Compound 1 
(XHE-III-74EE) 
Figure 40: Mucin volume densities of mouse lungs treated with compound 1. CTL: Non-challenged; vehicle (3 % DMSO, 20% 
propylene glycol and 77% water) given i.p. twice a day for 5 days; Dexamethasone (Dex) 4 mg/kg/day i.p. (5 days); Cmpd1: 20 
mg/kg b.i.d., i.p. for 5 days or 40 minutes before euthanasia; osmotic mini-pumps that release 20 mg/kg/day for 7 days. Data is 
represented as mean ± SEM, n = 7. ANOVA repeated measured was used for statistical analysis; *, **, *** indicates p<0.05 with 
reference to the vehicle injection/pumps mice. 
ovalbumin sensitized/challenged 
** 
*** 
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release of XHE-III-74EE at 20 mg/kg/day similarly did not significantly increase or decrease the 
mucin volume over a period of seven days.  
In the same paper, Compound 2, an α5-selective GABAAR positive modulator (SH-053-2F’-
R-CH3) was also tested in the same Ova S/C murine asthmatic inflammation model. The results 
are summarized in Figure 41.24  
Non-challenged mice in this study were challenged with i.n. saline twice a day for five 
days to determine the baseline levels of mucus produced by the mouse lung. Sensitization and 
challenge with ovalbumin again produced a comparable increase in mucin volume density levels 
to around 20 nL/mm2. SH-O53-2F’-R-CH3, when administered twice a day for five days at 
100mg/kg neither increased nor decreased the mucin volume density.   
Compound 2 
(SH-053-2F’-R-CH3) 
Figure 41: Mucin volume densities for Compound 2.1 CTL: non-challenged; vehicle gavage: vehicle (3 % DMSO, 20% propylene 
glycol and 77% water) administered twice daily for 5 days by oral gavage; Cmpd 2 gavage: 100 mg/kg administered twice 
daily for 5 days by oral gavage. Data is represented as mean ± SEM, n = 7. ANOVA repeated measured was used for statistical 
analysis; *, **, *** indicates p<0.05 with reference to the vehicle gavage mice. 
*** 
Ova S/C 
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In the same publication, Compound 3, an α4-selective GABAAR positive modulator (XHE-
III-74A) was also tested in the same Ova S/S murine asthmatic inflammation model. The results 
are summarized in Figure 42.24  
Non-challenged mice treated with i.p. injection of vehicle twice a day for five days were 
used to determine the baseline levels of mucus produced by the mouse lung. Sensitization and 
challenge again produced the expected mucin volume density levels. Again, XHE-III-74A when 
administered i.p. twice a day for five days at 20 mg/kg or when given as a single i.p. injection 40 
minutes before euthanasia neither increased nor decreased the mucin volume density. 
 
 
 
Compound 3 
(XHE-III-74A) 
Figure 42: Mucin volume densities for Compound 3.1 CTL: non-challenged; vehicle injection: vehicle (3 % DMSO, 20% 
propylene glycol and 77% water) administered i.p. twice daily for 5 days.; Cmpd 3 inj.: 20 mg/kg b.i.d., i.p. for 5 days or 40 
minutes before euthanasia. Data is represented as mean ± SEM, n = 7. ANOVA repeated measured was used for statistical 
analysis; *, **, *** indicates p<0.05 with reference to the vehicle injection mice. 
 
Ova S/C 
*** 
 
 
137 
 
 
Discussion  
None of the asthma drug candidates produced a result that deviated significantly from 
their respective ovalbumin sensitized and challenged positive control group. This was apparent 
both by visual inspection of the images and by quantitation. However, dexamethasone was 
effective at significantly reducing the mucus volume density.  
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• Synthetically conjugated siRNA to a recombinant polypeptide hormone that targets 
receptors on the surface of ovarian cancer cells 
• Gathered initial promising results for siRNA silencing delivery in an ovarian cancer cell line 
 
Modification of Phosphoramidites and Analysis by Crystallography May 2012-August 2012 
University of Toledo, Bryant-Friedrich Lab 
NSF REU Student Researcher 
 Attained an NSF scholarship to do research as a guest student in a participating 
professor’s lab 
 Modified DNA building blocks a sequence that was then analyzed by X-ray crystallography  
 Received the National Science Foundation’s scholarship to do undergraduate research as 
a guest student in a participating professor’s laboratory. 
 Learned about oxidative DNA damage and repair. 
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 Participated in small-molecule organic synthesis, DNA synthesis and analysis, and liquid 
crystal growth in the development and investigation of a xylose-sugar modified version of 
the Dickerson-Drew Dodecamer DNA sequence. 
 Operated instruments including: Biotage automated column, temperature regulator, DNA 
synthesizer, MALDI-TOF , OPC columns, HPLC, Carey UV, and UV-Vis spectrometer. 
 Received training for and implemented methods including: annealing, DNA synthesis, 
anaerobic conditions, 31P-NMR, melting temperature analysis, and X-ray crystallography. 
 
Organic Synthesis of TAAR Regulators    April 2011-June 2012 
Grand Valley State University, Hart Lab 
 Pursued the synthesis and purification of a proposed small molecule to investigate its 
properties as a regulator for the Trace Amine-Associated Receptor. 
 Received instruction for and implemented: 1H-NMR, 13C-NMR, IR, gravity columns, 
refluxing, and recrystallization.  
 
Organic Synthesis of Novel Antibacterials   January 2010-May 2010 
GVSU Chemistry Department     
 Worked from a general route to synthesize various small molecule antibiotics. 
 Honed general laboratory procedural skills, such as filtration, dissolution, extraction, TLC, 
and basic characterization methods. 
 
 
 
Instructional 
Experience: General Chemistry Teaching Assistant   August 2014-May 2019 
  University of Wisconsin—Milwaukee  
• Taught numerous discussion and laboratory sections  
• Revised laboratory manuals in Chemistry for Engineers class 
• Implemented additional formative assessment measures for students 
• Complied with restrictions for control and treatment classes employed by a professor for 
their educational research purposes 
 
Organic Chemistry Teaching Assistant   September 2013-June 2014 
  The University of Chicago 
• Worked closely with a small undergraduate class teaching their lecture and laboratory 
over the course of a school year 
• Dealt with entitlement complexes in highly privileged young adults 
• Adapted curriculum to suit the non-standard quarter system 
 
Long-term Substitute Teacher    December 2012-March 2013 
  Freedom Christian School 
• Diversified lesson format to better assist several students with accommodations 
• Adapted lessons from the primary teacher to enhance student learning and meet 
benchmarks 
• Motivated sophomores through seniors at small private high school on to higher 
achievement  
• Followed along with the usual teachers’ lessons, altering them to suit my teaching style 
• Worked with very small classroom sizes 
• Diversified lessons in high school physics and chemistry to suit several students with 
accommodations  
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Student Teacher     August 2012-December 2012 
  Union High School 
• Developed an understanding of the particular challenges facing inner-city and 
underfunded schools 
• Created a hands-on curriculum for high school biology and chemistry classes 
• Underwent many professional development sessions 
• Worked with very large class sizes 
• Developed trust and made peace in diverse classrooms during difficult racial tensions 
• Perfected practice with classroom management techniques  
 
Teacher Assistant      January 2012-April 2012 
Grandville Middle School 
• Gained insight to the instruction, management, and atmosphere of a middle school 
classroom. 
• Developed professional relationships with cooperating teachers, staff, and students. 
 
Structured Learning Assistance Facilitator  August 2010-December 2011 
Grand Valley State University  
• Managed a classroom of college freshmen. 
• Created worksheets and walk-throughs conducive to helping struggling students master 
general chemistry. 
 
Small Group Leader     August 2009-April 2012 
InterVarsity Christian Fellowship, USA: Grand Valley Chapter  
• Co-led in-depth studies of scripture with college students of all ages. 
• Fostered nurturing, caring, and supportive small group communities committed to 
building up leaders and reaching out to our campus and community. 
 
In-Class Tutor      Summer 2011 
Gerald R. Ford Job Corps Center 
 Assisted teacher with in-class one-on-one tutoring. 
 Developed a respect for and an understanding of inner-city school culture. 
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Presentations:  
• “Apparent ζ-potential as a tool to assess mechanical damages to the milk fat globule 
membrane.” Junior Seminar. Padnos Hall of Science 225, Grand Valley State University. 
3/22/2011. (oral presentation) 
• "Synthesis of Antibacterial Compound Library." Olivia White, Hart & Winchester Lab. Padnos 
Hall, Student Scholars Day, Grand Valley State University. 04/13/2011. (poster) 
• “Regioselective Nucleophilic Ring-Opening of Aziridines in the Synthesis of T1AM Analogues.” 
Olivia White and Jeremy Whitmore, Hart Lab. San Diego Conference Center, 243rd ACS National 
Meeting. 03/26/2012. (poster) 
• “Regioselective Nucleophilic Ring-Opening of Aziridines in the Synthesis of T1AM Analogues.” 
Olivia White, Hart Lab.  Manitou Hall 123, Grand Valley State University, Undergraduate 
Research Symposium. 04/02/2012. (presentation) 
• National Science Foundation Research Experience for Undergraduates Scholarship Recipient: 
Awarded 04/17/2012, for Summer 2012, University of Toledo. (award) 
• “Synthesis of 2’-Deoxyxylothymidine Phosphoramidite and Incorporation into Oligonucleotides 
for Crystal Structure Analysis.” Olivia White, Bryant-Friedrich Lab. Bowman-Oddy Hall, 
University of Toledo. 08/02/2012. (presentation) 
• “Development of a Direct VDR Binding Assay Based on Fluorescence Polarization.” Olivia Yu, 
Arnold Lab. Union Ballroom, University of Wisconsin—Milwaukee, Chemistry and Biochemistry 
Research Symposium. 04/03/2015. (poster) 
• “Organic Carbamates in Medicinal Chemistry and Drug Design.” Olivia Yu, Arnold Lab. 
Chemistry 180, University of Wisconsin—Milwaukee. 11/13/2015. (presentation) 
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• “Synthesis of Calcitroic Acid to Determine its Potential for Prevention of Colon Cancer.” Olivia 
Yu, Arnold Lab. University of Madison, International Chemical Biology Society. 10/25/2016. 
(poster) 
•  “Synthesis of Calcitroic Acid to Determine its Potential for Prevention of Colon Cancer.” Olivia 
Yu, Arnold Lab. Union Ballroom, University of Wisconsin—Milwaukee, Graduate Student 
Research Symposium. 10/28/2016. (poster) 
• “Investigation of the Biological Function of Calcitroic Acid and Its Phase Two Metabolites.” 
Olivia Yu, Elliot Di Milo, Viktoriia Senych, Kelly A Teske, Leggy A Arnold. Rosen Center, Orlando, 
Vitamin D Conference. 03/31/2017 (poster) 
• “Investigation of the Biological Function of Calcitroic Acid and Its Phase Two Metabolistes.” 
Olivia Yu, Elliot Di Milo, Viktoriia Senych, Kelly A Teske, Leggy A Arnold. Union Ballroom, 
University of Wisconsin—Milwaukee, Chemistry and Biochemistry Research Symposium. 
05/23/2017. (poster) 
• “Calcitroic Acid and the Vitamin D Receptor.” Olivia Yu. Kenwood Interdiscinplinary Research 
Complex, University of Wisconsin—Milwaukee, Nobel Graduate Student Symposium. 
09/29/2017 (distinguished presentation)  
• “Investigating Calcitroic Acid, Its Phase Two Metabolites, and Their Biological Function,” Olivia 
Yu, Elliot Di Milo, Leggy A Arnold. Barcelona International Convention Center, Barcelona, Spain. 
05/17/2018. (poster) 
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Yu, Elliot Di Milo, Leggy A Arnold. Kenwood Interdisciplinary Research Complex Hall, 
Milwaukee Analytical Chemistry Conference. 01/25/2019. (poster) 
• “Investigating Calcitroic Acid and Its Phase Two Metabolites,” Olivia Yu. Kenwood 
Interdisciplinary Research Complex 2175, Final Dissertation Defense. 04/22/2019 (oral 
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